Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Wednesday 05 February, 2020

GlaxoSmithKline PLC

Final Results

RNS Number : 0578C
GlaxoSmithKline PLC
05 February 2020
 

 

Issued: Wednesday, 5 February 2020, London U.K.

 

GSK delivers 2019 sales of £33.8 billion +10% AER, +8% CER (Pro-forma +4% CER*)

Total EPS 93.9p; +27% AER; +23% CER; Adjusted EPS 123.9p +4% AER, +1% CER

 


2019 financial and product highlights

·

Pharmaceuticals £17.6 billion +2% AER, flat CER; Vaccines £7.2 billion +21% AER, +19% CER; Consumer Healthcare £9 billion +17% AER, +17% CER (Pro-forma +2% CER*)

·

Shingrix sales £1.8 billion +>100% AER, +>100% CER driven by strong execution in the US

·

Total Respiratory sales £3,081 million +18% AER, +15% CER.  Trelegy £518 million +>100% AER, +>100% CER.  Nucala £768 million +36% AER, +33% CER

·

Total HIV sales £4.9 billion, +3% AER +1% CER.  Two-drug regimen sales £422 million

·

Total Group operating margin 20.6%.  Adjusted Group operating margin 26.6% reflecting increased R&D spending and impact of generic Advair in the US partly offset by improved Vaccines and Consumer Healthcare performance.  (Pharmaceuticals 26.2%; Vaccines 41.4%; Consumer Healthcare 20.8%)

·

Total EPS 93.9p +27% AER; +23% CER primarily reflecting reduced contingent consideration charges

·

Adjusted EPS 123.9p +4% AER, +1% CER reflecting operating performance and lower effective tax rate, partly offset by increased profit allocation to non-controlling interests

·

Net cash flow from operations £8.0 billion.  Free cash flow £5.1 billion

·

23p dividend declared for the quarter, 80p for FY19


Pipeline highlights

·

Continued strengthening of R&D pipeline in 2019: eight submissions, six positive pivotal trial results and four new assets progressed into pivotal trials

·

In 2020 expect at least six potential approvals in oncology, HIV, specialty and respiratory

·

Expect proof of concept readouts on several key pipeline assets including four oncology medicines and vaccines for COPD and RSV


2020 guidance

·

Expect Adjusted EPS to decline -1% to -4% CER

·

Expect 80p dividend for 2020


Preparing for two new companies

·

New programme initiated to prepare for separation of GSK into two companies:  New GSK, a biopharma company with an R&D approach focused on science related to the immune system, use of genetics and new technologies; and a new leader in Consumer Healthcare

·

As GSK increases investment in R&D and new product launches, the two-year separation programme aims to:


-

Drive a common approach to R&D across modalities with improved capital allocation


-

Align and improve capabilities and efficiencies of global support functions to support New GSK


-

Further optimise supply chain and portfolio, including divestments of non-core assets.  Strategic review of prescription dermatology underway


-

Prepare Consumer Healthcare to operate as a standalone company

·

Programme to target delivery of £0.7 billion of annual savings by 2022 with total costs estimated at £2.4 billion (of which £1.6 billion cash).  Programme expected to deliver improved operating performance, with meaningful improvements from 2022.  Anticipated divestment proceeds largely expected to cover programme cash costs

·

Additional one-time costs to prepare Consumer Healthcare for separation estimated at £600-700 million


 


2019 results

2019


Growth


Q4 2019


Growth


£m


£%


CER%


£m


£%


CER%













Turnover

33,754 


10 



8,899 



11 













Total operating profit

6,961 


27 


23 


1,902 


22 


29 

Total earnings per share

93.9p


27 


23 


26.2p



12 













Adjusted operating profit

8,972 




1,852 


(16)


(11)

Adjusted earnings per share

123.9p




24.8p


(21)


(16)













Net cash from operating activities

8,020 


(5)




3,453 


(16)



Free cash flow

5,073 


(11)




2,599 


(22)















 

The Total results are presented under 'Financial performance' on pages 11 and 26 and Adjusted results reconciliations are presented on pages 21, 22, 35 and 36.  Adjusted results are a non-IFRS measure that may be considered in addition to, but not as a substitute for, or superior to, information presented in accordance with IFRS.  Adjusted results are defined on page 9 and £% or AER% growth, CER% growth, free cash flow and other non-IFRS measures are defined on page 60.  GSK provides guidance on an Adjusted results basis only, for the reasons set out on page 10.  All expectations, guidance and targets regarding future performance and dividend payments should be read together with "Outlook, assumptions and cautionary statements" on pages 61 and 62.

*

Reported AER and CER growth rates include five months' results of former Pfizer consumer healthcare business.  Pro-forma CER growth rates are calculated as if the equivalent five months of Pfizer consumer healthcare business results, as reported by Pfizer, were included in the comparative period of 2018.  See "Pro-forma growth" on page 10.

 

 

Emma Walmsley, Chief Executive Officer, GSK said:

 

"GSK delivered a good performance in 2019 with growth in sales and earnings, together with strong cash generation.  We also made excellent progress in all three of our long-term priorities: Innovation, Performance and Trust, strengthening our pipeline, improving operational execution and reshaping the company.

 

"In 2020, our first priority remains Innovation, to progress our pipeline and support new product launches. Recent data readouts underpin our decision to further increase investment in R&D and these new products.  At the same time, we are again focused on operational execution, including delivering a successful integration in Consumer Healthcare, and we are also preparing for the future, starting a new two-year programme to get GSK ready for separation.

 

"All of this aims to support future growth, deliver significant value creation, and set up two new leading companies in biopharma and consumer healthcare, each with the opportunity to improve the health of hundreds of millions of people."

 

 

2020 guidance

 

We set out below earnings guidance for 2020.  This reflects our expectations for growth in key new products, and the start of a two-year period in which we will continue to increase investment in these products and in our R&D pipeline, alongside implementation of our new programme which will prepare the Group for separation.

 

In 2020 we expect Adjusted EPS to decline in the range of -1% to -4% at CER.  This guidance excludes any impact in 2020 from any further material divestments beyond those previously announced and any potential impact on our business from the Coronavirus outbreak.

 

All expectations, guidance and targets regarding future performance and dividend payments should be read together with "Outlook, assumptions and cautionary statements" on pages 61 and 62.

 

If exchange rates were to hold at the closing rates on 31 January 2020 ($1.31/£1, €1.19/£1 and Yen 143/£1) for the rest of 2020, the estimated negative impact on 2020 Sterling turnover growth would be around 3% and if exchange gains or losses were recognised at the same level as in 2019, the estimated negative impact on 2020 Sterling Adjusted EPS growth would be around 5%.

 

 

Results presentation

 

A webcast of the quarterly results presentation hosted by Emma Walmsley, GSK CEO, will be held at 2pm GMT on 5 February 2020.  Presentation materials will be published on www.gsk.com prior to the webcast and a transcript of the webcast will be published subsequently.

 

Information available on GSK's website does not form part of, and is not incorporated by reference into, this Results Announcement.

 

 

Operating performance - 2019

 

Turnover



2019









 



£m

 

Growth

£%

 

Growth

CER%









Pharmaceuticals

 

 

17,554 

 

 

Vaccines

 

 

7,157 

 

21 

 

19 

Consumer Healthcare

 

 

8,995 

 

17 

 

17 









 

 

 

33,706 

 

 









Corporate and other unallocated turnover

 

 

48 

 

 

 

 









Group turnover

 

 

33,754 

 

10 

 









Pro-forma growth

 

 

 

 

 

 









 

Group turnover for the year increased 10% AER, 8% CER to £33,754 million, with growth delivered by Vaccines and Consumer Healthcare and Pharmaceuticals flat at CER.  Pro-forma turnover growth for the Group was 4% CER.

 

Pharmaceuticals turnover in the year was £17,554 million, up 2% AER, but flat at CER.  HIV sales were up 3% AER, 1% CER, to £4,854 million, with growth in Juluca and Dovato partly offset by declines in Triumeq and Tivicay.  Respiratory sales were up 18% AER, 15% CER, to £3,081 million, on growth of Trelegy Ellipta and Nucala.  Sales of Established Pharmaceuticals were £8,776 million, down 7% AER, 8% CER, including the impact of loss of exclusivity of Advair.

 

Vaccines turnover grew 21% AER, 19% CER to £7,157 million, primarily driven by growth in sales of ShingrixMeningitis vaccines also contributed significantly to growth.

 

Consumer Healthcare sales grew 17% AER, 17% CER to £8,995 million.  On a pro-forma basis, sales grew 2%, driven by strong performance in the Oral health category, partly offset by a decline in Skin health. 

 

Operating profit

Total operating profit for the year was £6,961 million compared with £5,483 million in 2018.  Adjusted operating profit was £8,972 million, up 3% AER, but flat at CER on a turnover increase of 8% CER.  The Adjusted operating margin of 26.6% was down 1.8 percentage points at AER, 2.1 percentage points at CER and down 1.9 percentage points CER on a pro-forma basis.  Reduced re-measurement charges on the contingent consideration liabilities and an increase in value of the shares in Hindustan Unilever Limited to be received on the disposal of Horlicks and other brands were partly offset by increased charges for Major restructuring, primarily arising from write-downs in manufacturing sites.

 

The reduction in pro-forma Adjusted operating profit primarily reflected continuing price pressure, particularly in Respiratory, investment in R&D including a significant increase in Oncology and investments in promotional product support.  This was partly offset by the benefit from sales growth, particularly Vaccines, a more favourable mix in Vaccines and Consumer Healthcare, favourable inventory adjustments in Vaccines and continued tight control of ongoing costs across all three businesses. 

 

Earnings per share

Total earnings per share for the year was 93.9p, compared with 73.7p in 2018.  Adjusted EPS of 123.9p compared with 119.4p in 2018, up 4% AER, 1% CER, with Adjusted operating profit flat at CER.  The improvement primarily resulted from a reduced effective tax rate and an increased share of after tax profits of associates as a result of a non-recurring income tax benefit in Innoviva, partly offset by increased net finance costs and a higher non-controlling interest allocation of Consumer Healthcare profits.

 

Cash flow

Net cash inflow from operating activities was £8,020 million (2018: £8,421 million) and free cash flow was £5,073 million (2018: £5,692 million).  The reduction primarily reflected the adverse timing of payments for returns and rebates, the initial step-down impact from US Advair generic competition, increased capital expenditure and higher payments for restructuring and significant legal matters.

 

 

Operating performance - Q4 2019

 

Turnover



Q4 2019









 



£m

 

Growth

£%

 

Growth

CER%









Pharmaceuticals

 

 

4,558 

 

(5)

 

(4)

Vaccines

 

 

1,742 

 

18 

 

21 

Consumer Healthcare

 

 

2,571 

 

35 

 

37 









 

 

 

8,871 

 

 

10 









Corporate and other unallocated turnover

 

 

28 

 

 

 

 









Group turnover

 

 

8,899 

 

 

11 









Pro-forma growth

 

 

 

 

 

 









 

Group turnover increased 9% AER, 11% CER to £8,899 million in the quarter, with growth primarily driven by Vaccines and the acquisition of the Pfizer consumer healthcare business.  Pro-forma turnover growth for the Group was 2% CER.

 

Pharmaceuticals turnover in the quarter was £4,558 million, down 5% AER, 4% CER. Respiratory sales were up 8% AER, 9% CER to £892 million, on growth of Trelegy Ellipta and Nucala.  HIV sales of £1,257 million declined 1% AER but were flat at CER, with growth in Juluca and Dovato offset by a decline in Tivicay.  Sales of Established Pharmaceuticals declined 15% AER, 14% CER to £2,173 million, reflecting lower Advair sales.

 

Vaccines turnover grew 18% AER, 21% CER to £1,742 million, primarily driven by growth in sales of Shingrix.  Meningitis vaccines also contributed to growth, but Influenza vaccines sales declined primarily due to the impact of favourable US phasing in Q3 2019.

 

Consumer Healthcare sales grew 35% AER, 37% CER to £2,571 million in the quarter.  On a pro-forma basis, sales were flat, with strong growth in Oral health offset by declines in other categories, including the impact of some inventory level adjustments.

 

Operating profit

Total operating profit was £1,902 million in Q4 2019 compared with £1,554 million in Q4 2018.  Adjusted operating profit was £1,852 million, 16% lower than Q4 2018 at AER and 11% lower at CER on a turnover increase of 11% CER.  The Adjusted operating margin of 20.8% was down 6.0 percentage points at AER, 5.2 percentage points at CER and down 4.8 percentage points CER on a pro-forma basis.

 

Re-measurement credits on the contingent consideration liabilities, increased profit on disposals and reduced restructuring costs were partly offset by the unwind of the fair value uplift on inventory arising on completion of the Consumer Healthcare Joint Venture with Pfizer and a decrease in the value of the shares in Hindustan Unilever Limited.  GSK expects the transaction to complete around the end of Q1 2020, subject to legal and regulatory approvals.  Operating profit was also impacted by increased investment in R&D, investments in promotional product support, and continuing price pressure, together with a non-restructuring related write-down in a manufacturing site.  This was partly offset by the benefit from sales growth, particularly in Vaccines, a more favourable mix in Vaccines and continued tight control of ongoing costs across all three businesses.

 

Earnings per share

Total earnings per share was 26.2p, compared with 24.7p in Q4 2018.  Adjusted EPS of 24.8p compared with 31.2p in Q4 2018, down 21% AER, 16% CER, on an 11% CER decrease in Adjusted operating profit.  This reflected an increased non-controlling interest allocation of Consumer Healthcare profits and increased net finance costs, partly offset by a reduced effective tax rate.

 

Cash flow

Net cash inflow from operating activities was £3,453 million (Q4 2018: £4,119 million) and free cash flow was £2,599 million (Q4 2018: £3,317 million).  The reduced free cash flow primarily reflected  the adverse timing of payments for returns and rebates, the step-down impact from US Advair generic competition, higher significant legal payments and lower operating profits.

 

 

R&D pipeline

 

39 medicines in development, 15 Vaccines

 

Pipeline news flow highlights since Q3 2019:

 

Oncology

 

Zejula (niraparib, PARP inhibitor)

·

A regulatory application was submitted to the US FDA for the use of Zejula in ovarian cancer as first-line maintenance based on the results of the PRIMA study.

·

Data from the OPAL study assessing the safety and efficacy of new treatment combinations in patients with recurrent, platinum resistant ovarian cancer are in-house and analysis is ongoing.

 

Belantamab mafodotin (GSK2857916, BCMA immunoconjugate)

·

Pivotal data from the DREAMM-2 study of belantamab mafodotin in relapsed/refractory multiple myeloma patients were published in The Lancet Oncology demonstrating a clinically meaningful overall response rate. 

·

The US FDA granted priority review of belantamab mafodotin for patients with relapsed/refractory multiple myeloma.  Approval is expected in H1 2020.

·

The European Medicines Agency's (EMA) Committee for Human Medicinal Products accepted for accelerated assessment the marketing authorisation application for belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma.

·

The first patient was dosed in the DREAMM-9 pivotal study of belantamab mafodotin in combination for the first-line treatment of multiple myeloma.

 

Dostarlimab (TSR-042, PD-1 antagonist)

·

A regulatory application was submitted to the US FDA for second line treatment of patients with endometrial cancer based on the results of the GARNET study.

 

GSK3359609 (ICOS agonist)

·

The first patient was dosed in the phase II/III INDUCE-3 study of GSK'609 in combination with pembrolizumab in first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

 

GSK3326595 (PRMT5 inhibitor)

·

Proof of concept was achieved for GSK'595 in adenoid cystic carcinoma (ACyC).  Data from additional cohorts in 2020 will inform next steps.

 

GSK2636771 (PI3kb inhibitor)

·

GSK'771 for cancer was terminated as part of ongoing portfolio prioritisation.

 

HIV/Infectious diseases

 

Tivicay (dolutegravir)

·

Regulatory applications were submitted to the US FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children with HIV.

 

Cabotegravir + rilpivirine

·

A complete response letter was received from the US FDA for the use of investigational cabotegravir and rilpivirine long-acting regimen for treatment of HIV-1 infection in virologically supressed adults.

 

Fostemsavir (attachment inhibitor)

·

Regulatory applications were submitted to the US FDA and the EMA for fostemsavir, an investigational, first-in-class attachment inhibitor for heavily treatment-experienced adults with multi-drug resistant HIV-1 infection who are unable to form a suppressive regimen.

 

GSK3810109 (broadly neutralising antibody)

·

An exclusive licensing agreement was announced with the US National Institutes of Health for the investigational broadly neutralising antibody (bNAb) N6LS, with potential for long-acting HIV treatment and prevention.

 

Immuno-inflammation

 

Benlysta (belimumab)

·

Positive phase III headline results were reported from the BLISS-LN study of Benlysta in patients with lupus nephritis.  Regulatory submission is expected in H1 2020.

·

Preliminary data from a small proof of mechanism study with belimumab + rituximab for Sjogren's syndrome are in-house.  Additional data are needed and the study is ongoing.

 

GSK3358699 (targeted BET inhibitor)

·

GSK'699 for rheumatoid arthritis was moved back to research.

 

Respiratory

 

Trelegy (FF/UMEC/VI)

·

Trelegy received regulatory approval for COPD in China.

 

Nucala (mepolizumab)

·

Positive data from the pivotal study of Nucala in the treatment of patients with Hypereosinophilic Syndrome (HES) demonstrated a reduction in flares for this rare disease.  Regulatory submission is expected in 2020.

·

The first patient was dosed in the pivotal MATINEE study of Nucala in patients with COPD characterised by frequent exacerbations and eosinophil level.  

 

Other pharmaceuticals

 

Daprodustat

·

Futility analysis has been performed on phase III cardiovascular outcome studies which are continuing without modification.

 

Vaccines

 

Shingrix

·

A file was submitted in the EU to achieve a broadened indication aiming at covering immunocompromised populations.

 

Bexsero

·

Two independent meningitis B studies published in the New England Journal of Medicine demonstrated the real-world impact of Bexsero in reducing disease in infants and underscored the need for individual protection among adolescents.

 

Menveo

·

The US FDA approved the indication of a single booster dose administration of Menveo to individuals aged 15 to 55 years who are at continued risk of meningococcal disease if at least four years have elapsed since a previous dose.

 

RSV maternal

·

RSV maternal progressed to phase II with the start of the first time in human trial in pregnant women.

 

Tuberculosis vaccine

·

Our phase II tuberculosis vaccine candidate was licensed to the Bill & Melinda Gates Medical Research Institute for continued development.

 

HIV vaccine

·

Data from the HVTN 702 study of our HIV vaccine candidate for the developing world did not meet the required success criteria.  Further development of this vaccine candidate has been discontinued.

 

 

Contents

Page

 

 

Total and Adjusted results

9

Financial performance -  2019

11

Financial performance - three months ended 31 December 2019

26

Cash generation

39

Returns to shareholders

40

 

 

Income statements

42

Statement of comprehensive income - year ended 31 December 2019

43

Statement of comprehensive income - three months ended 31 December 2019

44

Pharmaceuticals turnover - year ended 31 December 2019

45

Pharmaceuticals turnover - three months ended 31 December 2019

46

Vaccines turnover - year ended 31 December 2019

47

Vaccines turnover - three months ended 31 December 2019

48

Balance sheet

49

Statement of changes in equity

50

Cash flow statement - year ended 31 December 2019

51

Segment information

52

Legal matters

54

Additional information

55

Reconciliation of cash flow to movements in net debt

59

Net debt analysis

59

Free cash flow reconciliation

59

Reporting definitions

60

Outlook, assumptions and cautionary statements

61

 

 

Contacts

 

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

 

 

GSK enquiries:




UK Media enquiries:

Simon Steel

+44 (0) 20 8047 5502

(London)


Tim Foley

+44 (0) 20 8047 5502

(London)


Mary Hinks-Edwards

+44 (0) 20 8047 5502

(London)





US Media enquiries:

Kristen Neese

+1 215 751 3335

(Philadelphia)





Analyst/Investor enquiries:

Sarah Elton-Farr

+44 (0) 20 8047 5194

(London)


James Dodwell

+44 (0) 20 8047 2406

(London)


Danielle Smith

+44 (0) 20 8047 7562

(London)


Jeff McLaughlin

+1 215 751 7002

(Philadelphia)

 

 

Registered in England & Wales:

No. 3888792


Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

Total and Adjusted results

 

Total reported results represent the Group's overall performance.

 

GSK also uses a number of adjusted, non-IFRS, measures to report the performance of its business.  Adjusted results and other non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS.  Adjusted results are defined below and pro-forma growth and other non-IFRS measures are defined on page 60.

 

GSK believes that Adjusted results, when considered together with Total results, provide investors, analysts and other stakeholders with helpful complementary information to understand better the financial performance and position of the Group from period to period, and allow the Group's performance to be more easily compared against the majority of its peer companies.  These measures are also used by management for planning and reporting purposes.  They may not be directly comparable with similarly described measures used by other companies.

 

GSK encourages investors and analysts not to rely on any single financial measure but to review GSK's quarterly results announcements, including the financial statements and notes, in their entirety.

 

GSK is committed to continuously improving its financial reporting, in line with evolving regulatory requirements and best practice.  In line with this practice, GSK expects to continue to review and refine its reporting framework.

 

Adjusted results exclude the following items from Total results, together with the tax effects of all of these items:

 

·

amortisation of intangible assets (excluding computer software)

·

impairment of intangible assets (excluding computer software) and goodwill

·

Major restructuring costs, which include impairments of tangible assets and computer software, (under specific Board approved programmes that are structural, of a significant scale and where the costs of individual or related projects exceed £25 million), including integration costs following material acquisitions

·

transaction-related accounting or other adjustments related to significant acquisitions

·

proceeds and costs of disposal of associates, products and businesses; significant legal charges (net of insurance recoveries) and expenses on the settlement of litigation and government investigations; other operating income other than royalty income, and other items

 

Costs for all other ordinary course smaller scale restructuring and legal charges and expenses are retained within both Total and Adjusted results.

 

As Adjusted results include the benefits of Major restructuring programmes but exclude significant costs (such as significant legal, major restructuring and transaction items) they should not be regarded as a complete picture of the Group's financial performance, which is presented in Total results.  The exclusion of other Adjusting items may result in Adjusted earnings being materially higher or lower than Total earnings.  In particular, when significant impairments, restructuring charges and legal costs are excluded, Adjusted earnings will be higher than Total earnings.

 

GSK is undertaking a number of Major restructuring programmes in response to significant changes in the Group's trading environment or overall strategy, or following material acquisitions.  Costs, both cash and non-cash, of these programmes are provided for as individual elements are approved and meet the accounting recognition criteria.  As a result, charges may be incurred over a number of years following the initiation of a Major restructuring programme.

 

Significant legal charges and expenses are those arising from the settlement of litigation or government investigations that are not in the normal course and materially larger than more regularly occurring individual matters.  They also include certain major legacy matters.

 

Reconciliations between Total and Adjusted results, providing further information on the key Adjusting items, are set out on pages 21, 22, 35 and 36.

 

GSK provides earnings guidance to the investor community on the basis of Adjusted results.  This is in line with peer companies and expectations of the investor community, supporting easier comparison of the Group's performance with its peers.  GSK is not able to give guidance for Total results as it cannot reliably forecast certain material elements of the Total results, particularly the future fair value movements on contingent consideration and put options that can and have given rise to significant adjustments driven by external factors such as currency and other movements in capital markets.

 

Pro-forma growth

The acquisition of the Pfizer consumer healthcare business completed on 31 July 2019 and so GSK's reported results include five months of results of the former Pfizer consumer healthcare business from 1 August 2019.

 

The Group has presented pro-forma growth rates at CER for turnover, Adjusted operating profit and operating profit by business taking account of this transaction.  Pro-forma growth rates for the quarter are calculated comparing reported results for Q4 2019, calculated applying the exchange rates used in the comparative period, with the results for Q4 2018 adjusted to include the equivalent three months of results of the former Pfizer consumer healthcare business during Q4 2018, as consolidated (in US$) and included in Pfizer's US GAAP results.  Similarly, pro-forma growth rates at CER for 2019 are calculated comparing reported results for 2019, calculated applying the exchange rates used in the comparative period, with the results for 2018, adjusted to include the equivalent five months of results of the former Pfizer consumer healthcare business, as consolidated (in US$) and included in Pfizer's US GAAP results.

 

ViiV Healthcare

ViiV Healthcare is a subsidiary of the Group and 100% of its operating results (turnover, operating profit, profit after tax) are included within the Group income statement. 

 

Earnings are allocated to the three shareholders of ViiV Healthcare on the basis of their respective equity shareholdings (GSK 78.3%, Pfizer 11.7% and Shionogi 10%) and their entitlement to preferential dividends, which are determined by the performance of certain products that each shareholder contributed.  As the relative performance of these products changes over time, the proportion of the overall earnings allocated to each shareholder also changes.  In particular, the increasing proportion of sales of dolutegravir-containing products has a favourable impact on the proportion of the preferential dividends that is allocated to GSK.  Adjusting items are allocated to shareholders based on their equity interests.  GSK was entitled to approximately 85% of the Total earnings and 82% of the Adjusted earnings of ViiV Healthcare for 2019.

 

As consideration for the acquisition of Shionogi's interest in the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi received the 10% equity stake in ViiV Healthcare and ViiV Healthcare also agreed to pay additional future cash consideration to Shionogi, contingent on the future sales performance of the products being developed by that joint venture, principally dolutegravir.  Under IFRS 3 'Business combinations', GSK was required to provide for the estimated fair value of this contingent consideration at the time of acquisition and is required to update the liability to the latest estimate of fair value at each subsequent period end.  The liability for the contingent consideration recognised in the balance sheet at the date of acquisition was £659 million.  Subsequent re-measurements are reflected within other operating income/expense and within Adjusting items in the income statement in each period.  At 31 December 2019, the liability, which is discounted at 8.5%, stood at £5,103 million, on a post-tax basis.

 

Cash payments to settle the contingent consideration are made to Shionogi by ViiV Healthcare each quarter, based on the actual sales performance of the relevant products in the previous quarter.  These payments reduce the balance sheet liability and hence are not recorded in the income statement.  The cash payments made to Shionogi by ViiV Healthcare in 2019 were £865 million. 

 

Because the liability is required to be recorded at the fair value of estimated future payments, there is a significant timing difference between the charges that are recorded in the Total income statement to reflect movements in the fair value of the liability and the actual cash payments made to settle the liability.

 

Further explanation of the acquisition-related arrangements with ViiV Healthcare are set out on pages 41 and 42 of the Annual Report 2018.

 

 

Financial performance -  2019

 

Total results

 

The Total results for the Group are set out below.

 


2019

£m


2018

£m


Growth

£%


Growth

CER%









Turnover

33,754 

 

30,821 

 

10 

 









Cost of sales

(11,863)

 

(10,241)

 

16 

 

16 









Gross profit

21,891 

 

20,580 

 

 









Selling, general and administration

(11,402)

 

(9,915)

 

15 

 

13 

Research and development

(4,568)

 

(3,893)

 

17 

 

15 

Royalty income

351 

 

299 

 

17 

 

17 

Other operating income/(expense)

689 

 

(1,588)

 

 

 

 









Operating profit

6,961 

 

5,483 

 

27 

 

23 









Finance income

98 

 

81 

 

 

 

 

Finance expense

(912)

 

(798)

 

 

 

 

Profit on disposal of associates

- 

 

 

 

 

 

Share of after tax profits of

  associates and joint ventures

74 

 

31 

 

 

 

 









Profit before taxation

6,221 

 

4,800 

 

30 

 

25 









Taxation

(953)

 

(754)

 

 

 

 

Tax rate %

15.3%

 

15.7%

 

 

 

 









Profit after taxation

5,268 

 

4,046 

 

30 

 

26 









Profit attributable to non-controlling

  interests

623 

 

423 

 

 

 

 

Profit attributable to shareholders

4,645 

 

3,623 

 

 

 

 









 

5,268 

 

4,046 

 

30 

 

26 









Earnings per share

93.9p

 

73.7p

 

27 

 

23 









 

 

Adjusted results

 

The Adjusted results for the Group are set out below.  Reconciliations between Total results and Adjusted results for 2019 and 2018 are set out on pages 21 and 22.

 


2019












£m


% of

turnover


Growth

£%


Reported

growth

CER%


Pro-forma

growth

CER%











Turnover

33,754 

 

100 

 

10 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

(10,079)


(29.9)

 

10 

 

10 


5 

Selling, general and

  administration

(10,715)


(31.7)

 

13 

 

12 


7 

Research and development

(4,339)


(12.9)

 

16 

 

14 


13 

Royalty income

351 


1.1 

 

17 

 

17 


17 











Adjusted operating profit

8,972 

 

26.6 

 

 

 

(3)











Adjusted profit before tax

8,236 



 

2 

 

(1)



Adjusted profit after tax

6,918 



 

6 

 

3 



Adjusted profit attributable to

  shareholders

6,131 



 

4 

 

1 













Adjusted earnings per share

123.9p

 

 

 

 

 

 











 

 

Operating profit by business

2019












£m


% of

turnover


Growth

£%


Reported

growth

CER%


Pro-forma

growth

CER%











Pharmaceuticals

7,964 

 

45.4 

 

(5)

 

(8)

 

(8)

Pharmaceuticals R&D*

(3,369)

 

 

 

26 

 

23 

 

23 











Total Pharmaceuticals

4,595 


26.2 

 

(20)

 

(22)


(22)

Vaccines

2,966 


41.4 

 

53 

 

46 


46 

Consumer Healthcare

1,874 


20.8 

 

24 

 

22 


4 











 

9,435 

 

28.0 

 

 

 

(3)

Corporate & other unallocated

  costs

(463)

 

 

 

 

 

 

 

 











Adjusted operating profit

8,972 


26.6 

 

3 

 

- 


(3)











 

*

Operating profit of Pharmaceuticals R&D segment, which is the responsibility of the Chief Scientific Officer and President, R&D.  It excludes ViiV Healthcare R&D expenditure, which is reported within the Pharmaceuticals segment.

 

 

Turnover

 

Pharmaceuticals turnover

 


2019








£m


Growth

£%


Growth

CER%







Respiratory

3,081

 

18 

 

15 

HIV

4,854

 

 

Immuno-inflammation

613

 

30 

 

25 

Oncology

230

 

 

Established Pharmaceuticals

8,776

 

(7)

 

(8)







 

17,554

 

 

 

 

 

 

 

 

US

7,402

 

(1)

 

(4)

Europe

4,125

 

 

International

6,027

 

 







 

17,554

 

 







 

Pharmaceuticals turnover in the year was £17,554 million, up 2% AER, but flat at CER.  HIV sales were up 3% AER, 1% CER, to £4,854 million, with growth in Juluca and Dovato partly offset by declines in Triumeq and Tivicay.  Respiratory sales were up 18% AER, 15% CER, to £3,081 million, on growth of Trelegy Ellipta and Nucala.  Sales of Established Pharmaceuticals were £8,776 million, down 7% AER, 8% CER, including the impact of loss of exclusivity of Advair.

 

In the US, sales declined 1% AER, 4% CER.  Continued growth of Nucala, Trelegy Ellipta and Benlysta was more than offset by the decline in Established Products including the loss of exclusivity of Advair.  Excluding Advair and Relvar/Breo Ellipta, which were impacted by genericisation of the ICS/LABA market, growth was 13% AER, 9% CER.  In Europe, sales grew 1% AER, 2% CER, with strong growth in Respiratory partly offset by a decline in Established Pharmaceuticals.  International grew 5% AER, 4% CER, with growth in all therapy areas.

 

Respiratory

Total Respiratory sales were up 18% AER, 15% CER, with strong growth in all regions.  Ellipta product sales grew 13% AER, 10% CER, with Europe up 26% AER, 27% CER and International up 29% AER, 27% CER on Trelegy and Relvar/Breo growth.  Nucala was up 36% AER, 37% CER in Europe and 56% AER, 50% CER in International.  In the US, Trelegy Ellipta and Nucala growth offset the decline in Relvar/Breo Ellipta on post generic ICS/LABA price pressure.

 

Sales of Nucala were £768 million in the year and grew 36% AER, 33% CER, with US sales of £453 million up 33% AER, 28% CER, including the impact of the new at-home use application.

 

Sales of Ellipta products were up 13% AER, 10% CER to £2,313 million driven by growth in Europe and International regions.  In the US, sales grew 4% AER, but were flat at CER, reflecting continued competitive pricing pressures for ICS/LABAs, post generic Advair.  In Europe, sales grew 26% AER, 27% CER, and in International by 29% AER, 27% CER.  Sales of Trelegy Ellipta contributed £518 million globally in the year, driven by an increase in US market share.

 

Relvar/Breo Ellipta sales were down 11% AER, 13% CER, driven by the US, where Relvar/Breo Ellipta declined 34% AER, 37% CER as a result of competitive pricing pressures and the impact of generic Advair on the US ICS/LABA market.  In Europe and International, Relvar/Breo Ellipta continued to grow, up 11% AER, 12% CER in Europe, and 21% AER, 19% CER in International.

 

HIV

HIV sales grew 3% AER, 1% CER to £4,854 million in the year.  The dolutegravir franchise grew 5% AER, 2% CER, delivering sales of £4,633 million.  The remaining portfolio, £221 million and 5% of total HIV sales, declined 27% AER, 27% CER and reduced the overall HIV growth by two percentage points at AER and one percentage point at CER.

 

Sales of dolutegravir products were £4,633 million, with Triumeq and Tivicay delivering sales of £2,549 million and £1,662 million, respectively.  The two-drug regimens, Juluca and Dovato, delivered sales of £422 million in the year with combined growth more than offsetting the decline in the three-drug regimen, Triumeq, as the business transitions to the new portfolio.

 

In the US, following the launch of Dovato in April 2019, combined sales of the two-drug regimens were £350 million.  Total dolutegravir sales grew 4% AER but were flat at CER, reflecting a year-on-year share decline as the business transitions to the new two-drug portfolio, offset by a net price benefit.  In Europe, total dolutegravir sales were flat at AER and flat at CER, with strong growth in market share offsetting price erosion and higher clawback payments.  Dovato and Juluca reported combined sales of £65 million.  International grew strongly with total dolutegravir sales growth of 22% AER, 22% CER, driven by Tivicay and Triumeq.

 

Oncology

Sales of Zejula, were £229 million in the period from the date of acquisition, comprising £134 million in the US and £95 million in Europe.

 

Immuno-inflammation

Sales of Benlysta in the year were up 30% AER, 25% CER to £613 million, including sales of the sub-cutaneous formulation of £268 million.  In the US, Benlysta grew 27% AER, 23% CER to £535 million.

 

Established Pharmaceuticals

Sales of Established Pharmaceuticals in the year were £8,776 million, down 7% AER, 8% CER.

 

Established Respiratory products declined 10% AER, 11% CER to £3,900 million, with the decline in Advair/Seretide partly offset by higher sales of Ventolin, Flovent and allergy products In the US, a generic version of Advair was launched in February, resulting in a 54% AER, 56% CER decline in the year.  In Europe, Seretide sales were down 16% AER, 16% CER to £502 million, reflecting continued competition from generic products and the transition of the Respiratory portfolio to newer products.  In International, sales of Seretide were flat at AER but down 1% CER.  Globally, Ventolin grew by 27% AER, 25% CER, driven by the strong uptake of an authorised generic version in the US.

 

The remainder of the Established Pharmaceuticals portfolio declined 5% AER, 6% CER to £4,876 million, including Lamictal down 8% AER, 10% CER to £566 million on generic competition and lower sales of Viread in International.  These declines were partly offset by Augmentin, up 6% AER, 6% CER to £602 million in the year, driven by strong growth in International. 

 

 

Vaccines turnover

 


2019








£m


Growth

£%


Growth

CER%







Meningitis

1,018

 

16 

 

15 

Influenza

541

 

 

Shingles

1,810

 

>100 

 

>100 

Established Vaccines

3,788

 

2 

 

1 







 

7,157

 

21 

 

19 

 

 

 

 

 

 

US

3,905

 

45 

 

39 

Europe

1,488

 

(5)

 

(4)

International

1,764

 

8 

 

9 







 

7,157

 

21 

 

19 







 

Vaccines turnover grew 21% AER, 19% CER to £7,157 million, primarily driven by growth in sales of Shingrix.  Meningitis vaccines also contributed to growth mainly due to Bexsero demand and share gains in the US together with stronger demand in International. Established Vaccines grew 2% AER, 1% CER to £3,788 million, primarily reflecting strong growth in Boostrix, Hepatitis, Synflorix and Infanrix/Pediarix, partly offset by lower Cervarix sales in International and supply constraints in MMRV vaccines.

 

Meningitis

Meningitis sales grew 16% AER, 15% CER to £1,018 million.  Bexsero sales grew 16% AER, 16% CER to £679 million, driven by demand and share gains in the US together with stronger demand in International and Europe, partly offset by the completion of the vaccination of catch-up cohorts in certain markets in Europe.  Menveo grew 15% AER, 13% CER, primarily reflecting improved supply and higher demand in International.

 

Influenza

Fluarix/FluLaval sales were up 3% AER, 1% CER to £541 million, reflecting strong sales execution in the US, partly offset by increased price competition in the US and lower demand in Europe.

 

Shingles

Shingrix recorded sales of £1,810 million, primarily driven by continued strong uptake and the favourable benefit of prior-period rebate adjustments in the US. Germany and Canada also contributed to growth.

 

Established Vaccines

Sales of DTPa-containing vaccines (Infanrix, Pediarix and Boostrix) grew 10% AER, 8% CER.  Infanrix/Pediarix sales grew 8% AER, 6% CER to £733 million, reflecting favourable year-on-year US CDC stockpile movements and stronger demand in International, partly offset by competitive pressures in Europe.  Boostrix sales were up 13% AER, 11% CER to £584 million mainly due to strong demand in International together with share gains and higher demand in the US.

 

Hepatitis vaccines grew 8% AER, 6% CER to £874 million, primarily due to favourable year-on-year CDC stockpile movements and the continued benefit from a competitor supply shortage in the US, partly offset by supply constraints and lower demand in Europe.

 

Synflorix sales grew 10% AER, 11% CER to £468 million, primarily due to stronger demand in International.

 

Rotarix sales were up 7% AER, 6% CER to £558 million, reflecting stronger demand in International and the US together with favourable phasing in International.

 

MMRV vaccines sales declined 24% AER, 23% CER to £232 million, largely driven by supply constraints in Europe and International.

 

Cervarix sales were down 64% AER, 64% CER to £50 million, reflecting lower demand and expected returns due to competitive pressure in China, together with lower demand elsewhere in International.

 

 

Consumer Healthcare turnover

 

 



2019









 



£m

 

Growth

£%

 

Growth

CER%









Wellness

 

 

4,526

 

15

 

14

Oral health

 

 

2,673

 

7

 

7

Nutrition

 

 

1,176

 

83

 

81

Skin health

 

 

620

 

7

 

7









 

 

 

8,995

 

17

 

17









US

 

 

2,583

 

41

 

36

Europe

 

 

2,456

 

5

 

6

International

 

 

3,956

 

13

 

14









 

 

 

8,995

 

17

 

17









Pro-forma growth

 

 

 

 

 

 

2









 

Consumer Healthcare sales grew 17% AER, 17% CER in 2019 to £8,995 million.  On a pro-forma basis, sales grew 2%, driven by strong performance in the Oral health category, partly offset by a decline in Skin health.  At a regional level, growth was driven by the US and International following the acquisition of the Pfizer portfolio, while on a pro-forma basis growth was driven primarily by the International region with strong performance in India and China.

 

Divestments and the phasing out of low margin contract manufacturing had a negative impact on pro-forma growth of approximately one percentage point.

 

Sales of the Consumer Healthcare business included five months of Pfizer brand sales arising after the creation of the Joint Venture.  The Pfizer brands have been included in the existing categories and geographic regions used to report Consumer Healthcare sales.  GSK expects to revise this category structure for reporting from Q1 2020 onwards.

 

Wellness

Wellness sales grew 15% AER, 14% CER to £4,526 million for the year.  On a pro-forma basis, sales were flat, with growth in Pain relief offset by a decline in Respiratory and the phasing out of low margin contract manufacturing.  Pain relief benefited from continued strong performance of Panadol and Advil with the latter reflecting ongoing recovery from now resolved supply issues.  Voltaren saw weaker performance and was also impacted by retail stock movements.  Respiratory sales declined as growth in Flonase was more than offset by weaker performance in Theraflu, following a strong cold and flu comparator in 2018.  Growth was also impacted by a decline in other Respiratory brands.

 

Oral health

Oral health sales grew 7% AER, 7% CER to £2,673 million.  Sensodyne saw double-digit, broad-based growth, with strong performance in the US and India benefiting from new product innovations.  Gum health grew in double digits with broad-based growth, while Denture care grew in mid-single digits.  Oral health growth was also impacted by a decline in sales of non-strategic brands.

 

Nutrition

Nutrition sales grew 83% AER, 81% CER to £1,176 million, largely due to the inclusion of the Pfizer vitamins, minerals and supplements portfolio.  On a pro-forma basis, sales were flat, reflecting the strong performance of Horlicks, offset by declines in other Nutrition products due to the alignment of in-market inventory levels of some Pfizer brands.  Growth was also impacted by the divestment of Horlicks and Maxinutrition in the UK.

 

Skin health

Skin health sales grew 7% AER, 7% CER to £620 million, largely due to the addition of Chapstick from the Pfizer portfolio.  On a pro-forma basis, sales declined in mid-single digits, largely due to divestments of small tail brands in the US and UK.

 

 

Operating performance

 

Cost of sales

Total cost of sales as a percentage of turnover was 35.1%, 1.9 percentage points higher at AER and 2.4 percentage points higher in CER terms compared with 2018.  This reflected an increase in the costs of Major restructuring programmes, primarily as a result of write downs in a number of manufacturing sites, the unwind of the fair market value uplift on inventory arising on completion of the Consumer Healthcare Joint Venture with Pfizer and increased amortisation of intangible assets.

 

Excluding these and other Adjusting items, Adjusted cost of sales as a percentage of turnover was 29.9%, 0.1 percentage points higher at AER and 0.5 percentage points higher at CER compared with 2018.  On a pro-forma basis, Adjusted cost of sales as a percentage of turnover was 29.9%, 0.3 percentage points higher at CER, than in 2018.  This reflected continued adverse pricing pressure in Pharmaceuticals, particularly in Respiratory, an unfavourable product mix in Pharmaceuticals and a number of non-restructuring related write downs in manufacturing sites.  This was partly offset by a more favourable product mix in Vaccines, primarily due to growth of Shingrix in the US, a favourable impact of inventory adjustments in Vaccines and a further contribution from integration and restructuring savings in Pharmaceuticals and Consumer Healthcare.

 

Selling, general and administration

Total SG&A costs as a percentage of turnover were 33.8%, 1.6 percentage points higher at AER and 1.6 percentage points higher at CER compared with 2018.  This included increased significant legal charges arising from the settlement of existing matters and provisions for ongoing litigation, costs related to the acquisition of the Pfizer consumer healthcare business and a reversal of an indemnity receivable from Novartis following a tax settlement, with an equivalent release of a tax provision which was reflected in the tax charge, as well as increased restructuring costs.

 

Excluding these and other Adjusting items, Adjusted SG&A costs as a percentage of turnover were 31.7%, 1.0 percentage point higher at AER than in 2018 and 1.0 percentage point higher on a CER basis.  On a pro-forma basis, Adjusted SG&A costs as a percentage of turnover was 31.7%, 0.8 percentage points higher at CER, compared with 2018.

 

The growth in Adjusted SG&A costs of 13% AER, 12% CER and 7% CER on a pro-forma basis reflected increased investment resulting from the acquisition of Tesaro and in promotional product support, particularly for new launches in Vaccines, Respiratory and HIV as well as increased costs for a number of legal settlements.  This was partly offset by the continuing benefit of restructuring in Pharmaceuticals and the tight control of ongoing costs, particularly in non-promotional spending across all three businesses.

 

Research and development

Total R&D expenditure was £4,568 million (13.5% of turnover), up 17% AER, 15% CER.  Adjusted R&D expenditure was £4,339 million (12.9% of turnover), 16% higher at AER, 14% higher at CER than in 2018.  On a pro-forma basis, Adjusted R&D expenditure grew 13% CER compared with 2018.

 

Pharmaceuticals R&D expenditure was £3,348 million, up 19% AER, 16% CER, with a significant increase in study and clinical trial material investment in Oncology compared with 2018 reflecting the progression of assets from the Tesaro acquisition, primarily Zejula and dostarlimab, and a number of other programmes, including belantamab mafodotin, NY-ESO, ICOS and bintrafusp alfa, as well as increased spending on the progression of key non-Oncology assets, such as aGM-CSF for rheumatoid arthritis.  This was partly offset by savings from the early phase portfolio reprioritisation in late 2018.  R&D expenditure in Vaccines and Consumer Healthcare was £718 million and £273 million, respectively.

 

Royalty income

Royalty income was £351 million (2018: £299 million), up 17% AER, 17% CER, primarily reflecting increased royalties on sales of Gardasil.

 

Other operating income/(expense)

Net other operating income of £689 million (2018: £1,588 million expense) primarily reflected the profit on disposal of rabies and tick-borne encephalitis vaccines (£306 million) and a number of other asset disposals together with an increase in value of the shares in Hindustan Unilever Limited to be received on the disposal of Horlicks and other Consumer Healthcare brands.  The cumulative increase in value since the signing of the proposed transaction was £240 million. 

 

Other income also included accounting credits of £127 million (2018: £1,846 million expense) arising from the re-measurement of the contingent consideration liabilities related to the acquisitions of the former Shionogi-ViiV Healthcare joint venture and the former Novartis Vaccines business and the liabilities for the Pfizer put option and Pfizer and Shionogi preferential dividends in ViiV Healthcare.  This included a re-measurement charge of £31 million (2018: £1,188 million) for the contingent consideration liability due to Shionogi, primarily arising from the unwind of the discounting, partly offset by changes in exchange rate assumptions and sales forecasts.  2018 also included a re-measurement charge of £658 million in relation to the Consumer Healthcare put option. 

 

Operating profit

Total operating profit was £6,961 million in 2019 compared with £5,483 million in 2018.  Reduced re-measurement charges on the contingent consideration liabilities, no Consumer Healthcare put option charge, increased profits on disposals and an increase in value of the shares in Hindustan Unilever Limited to be received on the disposal of Horlicks and other Consumer Healthcare brands were partly offset by increased charges for Major restructuring, primarily arising from write downs in a number of manufacturing sites and costs to integrate the Consumer Healthcare Joint Venture, and increased significant legal charges.  

 

Excluding these and other Adjusting items, Adjusted operating profit was £8,972 million, 3% higher than 2018 at AER but flat at CER on a turnover increase of 8% CER.  The Adjusted operating margin of 26.6% was 1.8 percentage points lower at AER, and 2.1 percentage points lower on a CER basis than in 2018.  On a pro-forma basis, Adjusted operating profit was 3% lower at CER on a turnover increase of 4% CER.  The Adjusted pro-forma operating margin of 26.6% was 1.9 percentage points lower on a CER basis than in 2018.

 

The reduction in pro-forma Adjusted operating profit primarily reflected continuing price pressure, particularly in Respiratory, including the impact of the launch of a generic version of Advair in the US in February 2019, investment in R&D including a significant increase in Oncology investment, partly on the assets from the Tesaro acquisition, and investments in promotional product support, particularly for new launches in Vaccines, HIV and Respiratory.  This was partly offset by the benefit from sales growth, particularly in Vaccines, a more favourable mix in Vaccines and Consumer Healthcare, favourable inventory adjustments in Vaccines and the continued benefit of restructuring with tight control of ongoing costs across all three businesses.

 

Contingent consideration cash payments which are made to Shionogi and other companies reduce the balance sheet liability and hence are not recorded in the income statement.  Total contingent consideration cash payments in 2019 amounted to £893 million (2018: £1,137 million).  This included cash payments made to Shionogi of £865 million (2018: £793 million).

 

Operating profit by business

Pharmaceuticals operating profit was £4,595 million, down 20% AER, 22% CER with turnover flat at CER.  The operating margin of 26.2% was 7.1 percentage points lower at AER than in 2018 and 7.2 percentage points lower on a CER basis.  This primarily reflected the increase in cost of sales percentage due to the continued impact of lower prices, particularly in Respiratory, including the impact of the launch of a generic version of Advair in the US in February 2019, an unfavourable product mix, primarily as a result of the decline in Advair and growth in lower margin products, a significant increase in Oncology R&D and investment in new product support and targeted priority markets, together with a number of non-restructuring related write downs in manufacturing sites and higher legal costs.  This was partly offset by the continued benefit of restructuring and tight control of ongoing costs and the benefits of re-prioritisation of the R&D portfolio.

 

Vaccines operating profit was £2,966 million, 53% AER, 46% CER higher than in 2018 on a turnover increase of 19% CER. The operating margin of 41.4% was 8.5 percentage points higher at AER than in 2018 and 7.3 percentage points higher on a CER basis.  This was primarily driven by enhanced operating leverage from strong sales growth, particularly Shingrix in the US, improved product mix and higher royalty income.  Increased SG&A investment to support business growth was partly offset by income from one-off settlements.

 

Consumer Healthcare operating profit was £1,874 million, up 24% AER, 22% CER higher on a turnover increase of 17% CER.  On a pro-forma basis, operating profit was £1,874 million, 4% CER higher on a turnover increase of 2% CER.  The operating margin of 20.8% was 1.0 percentage point higher at AER and 0.9 percentage points higher on a CER basis than in 2018.  The pro-forma operating margin of 20.8% was 0.5 percentage points higher on a CER basis.  This primarily reflected continued manufacturing restructuring savings, improved growth from higher margin power brands and the divestment of lower margin tail products, as well as tight control of other operating expenses, partly offset by increased investment in promotion.

 

Net finance costs

Total net finance costs were £814 million compared with £717 million in 2018.  Adjusted net finance costs were £810 million compared with £698 million in 2018.  The increase primarily reflected higher debt levels following the acquisition from Novartis of its stake in the Consumer Healthcare Joint Venture in June 2018 and the acquisition of Tesaro in January 2019, as well as an adverse comparison with a one-off accounting adjustment of £20 million to amortisation of interest charges in 2018.  This was partly offset by the benefit from older bonds being refinanced at lower interest rates, a fair value gain on interest rate swaps and interest of £23 million in Q3 2018 on an historic tax settlement.  Following the introduction of IFRS 16, 'Leases', finance costs included an unwind of the discount on the lease liability of £39 million in the year.

 

Share of after tax profits of associates and joint ventures

The share of after tax profits of associates was £74 million (2018: £31 million).  This included a one-off adjustment of £51 million to reflect GSK's share of increased after tax profits of Innoviva primarily as a result of a non-recurring income tax benefit.

 

Taxation

The charge of £953 million represented an effective tax rate on Total results of 15.3% (2018: 15.7%) and reflected the different tax effects of the various Adjusting items.  Tax on Adjusted profit amounted to £1,318 million and represented an effective Adjusted tax rate of 16.0% (2018: 19.0%), reflecting the impact of the settlement of a number of open issues with tax authorities.

 

Issues related to taxation are described in Note 14, 'Taxation' in the Annual Report 2018.  The Group continues to believe it has made adequate provision for the liabilities likely to arise from periods which are open and not yet agreed by tax authorities.  The ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of agreements with relevant tax authorities.

 

Non-controlling interests

The allocation of Total earnings to non-controlling interests amounted to £623 million (2018: £423 million).  The increase was primarily due to an increased allocation of ViiV Healthcare profits of £482 million (2018: £251 million) and higher net profits in some of the Group's other entities with non-controlling interests.  This was partly offset by the lower allocation of Consumer Healthcare profits of £70 million (2018: £117 million) following the buyout of Novartis' interest in June 2018 and the completion of the new Consumer Healthcare Joint Venture with Pfizer on 31 July 2019, and which included the unwind of the fair value uplift on acquired inventory.

 

The allocation of Adjusted earnings to non-controlling interests amounted to £787 million (2018: £674 million).  The increase in allocation reflected an increased allocation of Consumer Healthcare profits of £204 million (2018: £118 million), an increased allocation of ViiV Healthcare profits of £512 million (2018: £501 million) and higher net profits in some of the Group's other entities with non-controlling interests.

 

Earnings per share

Total earnings per share was 93.9p, compared with 73.7p in 2018.  The increase in earnings per share primarily reflected reduced re-measurement charges on the contingent consideration liabilities and put options, an increase in the value of the shares in Hindustan Unilever Limited to be received on the disposal of Horlicks and other Consumer Healthcare brands, a reduced effective tax rate and the increased share of after tax profit of the associate Innoviva. 

 

Adjusted EPS of 123.9p compared with 119.4p in 2018, up 4% AER, 1% CER, with Adjusted operating profit flat at CER.  The improvement primarily resulted from a reduced effective tax rate and an increased share of after tax profits of associates as a result of a non-recurring income tax benefit in Innoviva, partly offset by increased net finance costs and a higher non-controlling interest allocation of Consumer Healthcare profits.

 

Currency impact on 2019 results

The results for 2019 are based on average exchange rates, principally £1/$1.28,  £1/€1.14 and £1/Yen 139.  Comparative exchange rates are given on page 56.  The period-end exchange rates were £1/$1.32, £1/€1.18 and £1/Yen 143.

 

In 2019, turnover increased 10% AER, 8% CER.  Total EPS was 93.9p compared with 73.7p in 2018.  Adjusted EPS was 123.9p compared with 119.4p in 2018, up 4% AER, 1% CER.  The positive currency impact primarily reflected the weakness of Sterling, particularly against the US$ and Yen, partly offset by weakness in emerging market currencies, relative to 2018.  Exchange gains or losses on the settlement of intercompany transactions had a negligible impact on the positive currency impact of three percentage points on Adjusted EPS.

 

 

Adjusting items

The reconciliations between Total results and Adjusted results for 2019 and 2018 are set out below.

 

Year ended 31 December 2019

 


Total

results

£m

Intangible

amort-

isation

£m

Intangible

impair-

ment

£m

Major

restruct-

uring

£m

Transaction-

related

£m

Divestments,

significant

legal and

other items

£m

Adjusted

results

£m


------------

------------

------------

------------

------------

------------

------------

Turnover

33,754 






33,754 

Cost of sales

(11,863)

713 

30 

658 

383 

- 

(10,079)


------------

------------

------------

------------

------------

------------

------------

Gross profit

21,891 

713 

30 

658 

383 

- 

23,675 









Selling, general and administration

(11,402)


4 

332 

104 

247 

(10,715)

Research and development

(4,568)

64 

49 

114 


2 

(4,339)

Royalty income

351 






351 

Other operating income/(expense)

689 



1 

(142)

(548)

- 


------------

------------

------------

------------

------------

------------

------------

Operating profit

6,961 

777 

83 

1,105 

345 

(299)

8,972 









Net finance costs

(814)



5 


(1)

(810)

Share of after tax profits of

  associates and joint ventures

74 






74 


------------

------------

------------

------------

------------

------------

------------

Profit before taxation

6,221 

777 

83 

1,110 

345 

(300)

8,236 









Taxation

(953)

(156)

(17)

(208)

(124)

140 

(1,318)

Tax rate %

15.3%






16.0%


------------

------------

------------

------------

------------

------------

------------

Profit after taxation

5,268 

621 

66 

902 

221 

(160)

6,918 


------------

------------

------------

------------

------------

------------

------------

Profit attributable to

  non-controlling interests

623 




164 


787 









Profit attributable to

  shareholders

4,645 

621 

66 

902 

57 

(160)

6,131 


------------

------------

------------

------------

------------

------------

------------









Earnings per share

93.9p

12.6p

1.3p

18.2p

1.2p

(3.3)p

123.9p


------------

------------

------------

------------

------------

------------

------------

















Weighted average number of

  shares (millions)

4,947 






4,947 


------------






------------

 

 

Year ended 31 December 2018

 


Total

results

£m

Intangible

amort-

isation

£m

Intangible

impair-

ment

£m

Major

restruct-

uring

£m

Transaction-

related

£m

Divestments,

significant

legal and

other items

£m

Adjusted

results

£m


------------

------------

------------

------------

------------

------------

------------

Turnover

30,821 






30,821 

Cost of sales

(10,241)

536 

69 

443 

15 


(9,178)


------------

------------

------------

------------

------------

------------

------------

Gross profit

20,580 

536 

69 

443 

15 


21,643 









Selling, general and administration

(9,915)


2 

315 

98 

38 

(9,462)

Research and development

(3,893)

44 

45 

49 


20 

(3,735)

Royalty income

299 






299 

Other operating (expense)/income

(1,588)



2 

1,864 

(278)

- 


------------

------------

------------

------------

------------

------------

------------

Operating profit

5,483 

580 

116 

809 

1,977 

(220)

8,745 









Net finance costs

(717)



4 

(3)

18 

(698)

Profit on disposal of associates





(3)

- 

Share of after tax profits of

  associates and joint ventures

31 






31 


------------

------------

------------

------------

------------

------------

------------

Profit before taxation

4,800 

580 

116 

813 

1,974 

(205)

8,078 









Taxation

(754)

(109)

(19)

(170)

(239)

(244)

(1,535)

Tax rate %

15.7%






19.0%


------------

------------

------------

------------

------------

------------

------------

Profit after taxation

4,046 

471 

97 

643 

1,735 

(449)

6,543 


------------

------------

------------

------------

------------

------------

------------

Profit attributable to

  non-controlling interests

423 




251 


674 









Profit attributable to

  shareholders

3,623 

471 

97 

643 

1,484 

(449)

5,869 


------------

------------

------------

------------

------------

------------

------------









Earnings per share

73.7p

9.6p

2.0p

13.1p

30.2p

(9.2)p

119.4p


------------

------------

------------

------------

------------

------------

------------

















Weighted average number of

  shares (millions)

4,914 






4,914 


------------






------------

 

 

Major restructuring and integration

Within the Pharmaceuticals sector, the highly regulated manufacturing operations and supply chains and long lifecycle of the business mean that restructuring programmes, particularly those that involve the rationalisation or closure of manufacturing or R&D sites are likely to take several years to complete.

 

Total Major restructuring charges incurred in 2019 were £1,105 million (2018: £809 million), analysed as follows:

 


2019


2018














Cash

£m


Non-cash

£m


Total

£m


Cash

£m


Non-cash

£m


Total

£m













2018 major restructuring

  programme (incl. Tesaro)

227

 

572

 

799

 

279

 

90

 

369

Consumer Healthcare Joint

  Venture integration

  programme

248

 

4

 

252

 

-

 

-

 

-

Combined restructuring and

  integration programme

10

 

44

 

54

 

330

 

110

 

440













 

485

 

620

 

1,105

 

609

 

200

 

809













 

Cash charges primarily arose from restructuring of the manufacturing organisation, R&D and some administrative functions as well as the integration of Tesaro under the 2018 major restructuring programme and integration costs under the Consumer Healthcare Joint Venture integration programme.  Non-cash charges under the 2018 major restructuring programme primarily related to announced plans to restructure the manufacturing network.

 

Total cash payments made in 2019 were £645 million, £316 million for the existing Combined restructuring and integration programme (2018: £528 million) and £164 million (2018: £9 million) under the 2018 major restructuring programme including the settlement of certain charges accrued in previous quarters and a further £165 million relating to the Consumer Healthcare Joint Venture integration programme.

 

The analysis of Major restructuring charges by business was as follows:

 

 

2019

£m

 

2018

£m

 




Pharmaceuticals

651

 

563

Vaccines

58

 

104

Consumer Healthcare

321

 

72





 

1,030

 

739

Corporate & central functions

75

 

70

 




Total Major restructuring costs

1,105

 

809





 

The analysis of Major restructuring charges by Income statement line was as follows:

 

 

2019

£m

 

2018

£m

 




Cost of sales

658

 

443

Selling, general and administration

332

 

315

Research and development

114

 

49

Other operating expense

1

 

2

 




Total Major restructuring costs

1,105

 

809





 

The Combined restructuring and integration programme delivered incremental annual cost savings in the year of £0.3 billion.  The 2018 major restructuring programme delivered incremental cost savings in the year of £0.2 billion.

 

Total cash charges for the Combined restructuring and integration programme are now expected to be approximately £4.0 billion with non-cash charges of £1.4 billion.  The total of £5.4 billion represents a reduction of £0.3 billion from the originally approved £5.7 billion.  The programme has now delivered approximately £4.2 billion of annual savings, including an estimated currency benefit of £0.2 billion.  The programme is expected to deliver by the end of 2020 total annual savings of £4.3 billion on a constant currency basis, including an estimated benefit of £0.2 billion from currency on the basis of 2019 average exchange rates.  The programme is substantially complete and therefore GSK will cease external reporting of total costs and benefits of the Combined restructuring and integration programme from 2020 onwards.

 

The Group acquired Tesaro in January 2019, and is expected to incur around £50 million of integration and restructuring cash costs, leading to annual cost-saving benefits of around £50 million.  This has been added to and reported as part of the existing 2018 major restructuring programme.

 

The 2018 major restructuring programme, now including Tesaro, is expected to cost £1.75 billion over the period to 2021, with cash costs of £0.85 billion and non-cash costs of £0.9 billion, and is expected to deliver annual savings of around £450 million by 2021 (at 2019 rates).  These savings are intended to be fully re-invested to help fund targeted increases in R&D and commercial support of new products.

 

The completion of the new Consumer Healthcare Joint Venture with Pfizer is expected to realise substantial cost synergies, generating total annual cost savings of £0.5 billion by 2022 for expected cash costs of £0.7 billion and non-cash charges of £0.3 billion, plus additional capital expenditure of £0.2 billion.  Up to 25% of the cost savings are intended to be reinvested in the business to support innovation and other growth opportunities.

 

The Group has initiated a two-year Separation Preparation programme to prepare for the separation of GSK into two companies:  New GSK, a biopharma company with an R&D approach focused on science related to the immune system, the use of genetics and new technologies, and a new leader in Consumer Healthcare.  The programme aims to:

 

·

Drive a common approach to R&D with improved capital allocation

·

Align and improve the capabilities and efficiency of global support functions to support New GSK

·

Further optimise the supply chain and product portfolio, including the divestment of non-core assets.  A strategic review of prescription dermatology is underway

·

Prepare Consumer Healthcare to operate as a standalone company

 

The programme will target delivery of £0.7 billion of annual savings by 2022 and £0.8 billion by 2023, with total costs estimated at £2.4 billion, of which £1.6 billion is expected to be cash costs.  The proceeds of anticipated divestments are largely expected to cover the cash costs of the programme.

 

Additional one-time costs to prepare Consumer Healthcare for separation are estimated at £600-700 million, excluding transaction costs.

 

Transaction-related adjustments

Transaction-related adjustments resulted in a net charge of £345 million (2018: £1,977 million).  This included a net £127 million accounting credit for the re-measurement of the contingent consideration liabilities related to the acquisitions of the former Shionogi-ViiV Healthcare joint venture and the former Novartis Vaccines business and the liabilities for the Pfizer put option and Pfizer and Shionogi preferential dividends in ViiV Healthcare.

 

Charge/(credit)

2019

£m

 

2018

£m





Consumer Healthcare Joint Venture put option

- 

 

658 

Contingent consideration on former Shionogi-ViiV Healthcare joint venture

  (including Shionogi preferential dividends)

31 

 

1,188 

ViiV Healthcare put options and Pfizer preferential dividends

(234)

 

(58)

Contingent consideration on former Novartis Vaccines business

76 

 

58 

Release of fair value uplift on acquired Pfizer inventory

366 

 

Other adjustments

106 

 

131 





Total transaction-related charges

345 

 

1,977 





 

The £31 million charge relating to the contingent consideration for the former Shionogi-ViiV Healthcare joint venture represented an increase in the valuation of the contingent consideration due to Shionogi, primarily as a result of a £435 million unwind of the discount, partly offset by updated exchange rate assumptions and adjustments to sales forecasts.  The £234 million credit relating to the ViiV Healthcare put options and Pfizer preferential dividends represented a reduction in the valuation of the put option as a result of adjustments to multiples and sales forecasts as well as updated exchange rate assumptions.

 

Other adjustments included transaction costs arising on completion of the Consumer Healthcare Joint Venture with Pfizer and a reversal of an indemnity receivable from Novartis following a tax settlement, with an equivalent release of a tax provision.

 

An explanation of the accounting for the non-controlling interests in ViiV Healthcare is set out on page 10.

 

Divestments, significant legal charges and other items

Divestments and other items included a profit on disposal of rabies and tick-borne encephalitis vaccines (£306 million), a gain in the year of £143 million arising from the increase in value of the shares in Hindustan Unilever Limited to be received on the disposal of Horlicks and other Consumer Healthcare brands, as well as equity investment impairments and certain other Adjusting items together with the profit on a number of asset disposals.  A charge of £251 million (2018: £33 million) for significant legal matters included the settlement of existing matters as well as provisions for ongoing litigation.  Significant legal cash payments were £294 million (2018: £39 million).

 

 

Financial performance - Q4 2019

 

Total results

 

The Total results for the Group are set out below.

 


Q4 2019

£m


Q4 2018

£m


Growth

£%


Growth

CER%









Turnover

8,899 

 

8,197 

 

 

11 









Cost of sales

(3,248)

 

(2,904)

 

12 

 

14 









Gross profit

5,651 

 

5,293 

 

 









Selling, general and administration

(3,443)

 

(2,620)

 

31 

 

31 

Research and development

(1,243)

 

(1,076)

 

16 

 

17 

Royalty income

82 

 

79 

 

 

Other operating income/(expense)

855 

 

(122)

 

 

 

 









Operating profit

1,902 

 

1,554 

 

22 

 

29 









Finance income

11 

 

24 

 

 

 

 

Finance expense

(206)

 

(209)

 

 

 

 

Share of after tax profits of associates

  and joint ventures

4 

 

 

 

 

 









Profit before taxation

1,711 

 

1,374 

 

25 

 

32 









Taxation

(194)

 

(74)

 

 

 

 

Tax rate %

11.3%

 

5.4%

 

 

 

 









Profit after taxation

1,517 

 

1,300 

 

17 

 

23 









Profit attributable to non-controlling

  interests

218 

 

85 

 

 

 

 

Profit attributable to shareholders

1,299 

 

1,215 

 

 

 

 









 

1,517 

 

1,300 

 

17 

 

23 









Earnings per share

26.2p

 

24.7p

 

 

12 









 

 

Adjusted results

 

The Adjusted results for the Group are set out below.  Reconciliations between Total results and Adjusted results for Q4 2019 and Q4 2018 are set out on pages 35 and 36.

 


Q4 2019












£m


% of

turnover


Growth

£%


Reported

growth

CER%


Pro-forma

growth

CER%











Turnover

8,899 

 

100 

 

 

11 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

(2,848)


(32.0)

 

12 

 

15 


4 

Selling, general and

  administration

(3,117)


(35.0)

 

23 

 

23 


11 

Research and development

(1,164)


(13.1)

 

14 

 

16 


13 

Royalty income

82 


0.9 

 

4 

 

4 


4 











Adjusted operating profit

1,852 

 

20.8 

 

(16)

 

(11)

 

(17)











Adjusted profit before tax

1,659 



 

(18)

 

(13)



Adjusted profit after tax

1,452 



 

(13)

 

(8)



Adjusted profit attributable to

  shareholders

1,227 



 

(20)

 

(16)













Adjusted earnings per share

24.8p

 

 

 

(21)

 

(16)

 

 











 

 

Operating profit by business

Q4 2019












£m


% of

turnover


Growth

£%


Reported

growth

CER%


Pro-forma

growth

CER%











Pharmaceuticals

1,935 

 

42.5 

 

(17)

 

(15)

 

(15)

Pharmaceuticals R&D*

(927)

 

 

 

19 

 

21 

 

21 











Total Pharmaceuticals

1,008 


22.1 

 

(35)

 

(33)


(33)

Vaccines

578 


33.2 

 

38 

 

42 


42 

Consumer Healthcare

440 


17.1 

 

25 

 

33 


(8)











 

2,026 

 

22.8 

 

(13)

 

(10)

 

(15)

Corporate & other unallocated

  costs

(174)

 

 

 

 

 

 

 

 











Adjusted operating profit

1,852 


20.8 

 

(16)

 

(11)


(17)











 

*

Operating profit of Pharmaceuticals R&D segment, which is the responsibility of the Chief Scientific Officer and President, R&D.  It excludes ViiV Healthcare R&D expenditure, which is reported within the Pharmaceuticals segment.

 

 

Turnover

 

Pharmaceuticals turnover

 


Q4 2019








£m


Growth

£%


Growth

CER%







Respiratory

892

 

 

HIV

1,257

 

(1)

 

Immuno-inflammation

170

 

25 

 

26 

Oncology

66

 

 

Established Pharmaceuticals

2,173

 

(15)

 

(14)







 

4,558

 

(5)

 

(4)

 

 

 

 

 

 

US

1,958

 

(8)

 

(6)

Europe

1,048

 

(6)

 

(3)

International

1,552

 

(2)

 







 

4,558

 

(5)

 

(4)







 

Pharmaceuticals turnover in the quarter was £4,558 million, down 5% AER, 4% CER. Respiratory sales were up 8% AER, 9% CER to £892 million, on growth of Trelegy Ellipta and Nucala.  HIV sales of £1,257 million declined 1% AER but were flat at CER, with growth in Juluca and Dovato offset by a decline in Tivicay.  Sales of Established Pharmaceuticals declined 15% AER, 14% CER to £2,173 million, reflecting lower Advair sales following the generic launch in Q1 2019.  Established Pharmaceuticals growth in the quarter was impacted by both a European Relenza tender and post divestment inventory sales recorded in the prior year.

 

In the US, sales declined 8% AER, 6% CER.  Continued growth of Nucala, Trelegy Ellipta and Benlysta was more than offset by the decline in Established Products, including the loss of exclusivity of Advair.  Excluding Advair and Relvar/Breo Ellipta, which were impacted by genericisation of the ICS/LABA market, growth was 7% AER, 8% CER.  In Europe, sales declined 6% AER, 3% CER, with strong growth in Respiratory and from Zejula.  International sales declined 2% AER, but were flat at CER, with Respiratory growth offset by lower Established Pharmaceutical sales reflecting post divestment inventory sales in Q4 2018.

 

Respiratory

Total Respiratory sales were up 8% AER, 9% CER, with strong growth in Europe and International which saw growth in Ellipta products, including Relvar/Breo and Trelegy, and NucalaNucala sales grew 27% AER, 32% CER in Europe and 36% AER, 36% CER in International.  In the US, Trelegy Ellipta and Nucala growth was offset by a decline in Relvar/Breo Ellipta on post-generic ICS/LABA price pressure.

 

Sales of Nucala were £218 million in the quarter and grew 26% AER, 28% CER, with US sales up 23% AER, 24% CER to £132 million including the impact of the new at-home use application.

 

Sales of Ellipta products were up 3% AER, 4% CER to £674 million driven by growth in Europe and International regions.  In the US, sales declined 6% AER, 5% CER, reflecting continued competitive pricing pressures for Relvar/Breo, partly offset by ongoing growth in Trelegy Ellipta.  In Europe, Ellipta product sales grew 17% AER, 19% CER.  Sales of Trelegy Ellipta contributed £172 million globally in the quarter, driven by an increase in US market share.

 

Relvar/Breo Ellipta sales were down 19% AER, 19% CER.  In the US, Relvar/Breo Ellipta declined 42% AER, 41% CER impacted by US competitive pricing pressures and the impact of generic Advair on the US ICS/LABA market.  In Europe and International, Relvar/Breo Ellipta continued to grow, up 4% AER, 6% CER and 16% AER, 14% CER, respectively.

 

HIV

HIV sales of £1,257 million declined 1% AER but were flat at CER in the quarter.  The dolutegravir franchise was flat at AER, but grew 2% at CER, delivering sales of £1,208 million in the quarter.  The remaining portfolio, with sales of £49 million and 4% of total HIV sales, declined 31% AER, 30% CER and reduced the overall growth of total HIV by two percentage points in the quarter.

 

Sales of dolutegravir products were £1,208 million in the quarter, with Triumeq and Tivicay delivering sales of £638 million and £426 million, respectively.  The two-drug regimens, Juluca and Dovato, delivered sales of £144 million in the quarter, with combined growth more than offsetting the decline in the three-drug regimen, Triumeq, as the business transitions to the new portfolio.

 

In the US, following the launch of Dovato in April 2019, combined sales of the two-drug regimens were £116 million.  Total dolutegravir sales were flat at AER but grew 2% at CER, reflecting a year-on-year share decline as the business transitions to the new two-drug portfolio, more than offset by net price benefit.  In Europe, total dolutegravir sales declined 4% AER, 1% CER, with strong dolutegravir volume growth in the quarter more than offset by price erosion, higher clawback payments, and an adverse stocking pattern comparator in 2018.  Combined sales of Dovato and Juluca recorded sales of £25 million.  International continued to grow strongly with total dolutegravir sales growth of 9% AER, 11% CER, driven by Tivicay.

 

Oncology

Sales of Zejula, the newly acquired PARP inhibitor asset were £66 million in the quarter, comprising £37 million in the US and £29 million in Europe.

 

Immuno-inflammation

Sales of Benlysta in the quarter were up 23% AER, 24% CER to £170 million, including sales of the sub-cutaneous formulation of £79 million.  In the US, Benlysta grew 22% AER, 25% CER to £148 million.

 

Established Pharmaceuticals

Sales of Established Pharmaceuticals in the quarter were £2,173 million, down 15% AER, 14% CER.

 

Established Respiratory products declined 17% AER, 16% CER to £965 million.  In the US, Advair experienced its third full quarter of generic competition, resulting in a 65% AER, 64% CER decline.  Also in the US, Ventolin continued to benefit from strong uptake of an authorised generic version launched earlier in the year.  In Europe, Seretide sales were down 21% AER, 18% CER to £119 million, reflecting continued competition from generic products and the transition of the Respiratory portfolio to newer products.  In International, sales of Seretide were down 4% AER, 4% CER.

 

The remainder of the Established Pharmaceuticals portfolio declined by 14% AER, 12% CER to £1,208 million including Lamictal down 9% AER, 8% CER to £145 million on generic competition in the US and International, partially offset by growth in Augmentin in International.  Growth in the quarter was impacted by a European Relenza tender and post divestment inventory sales in the prior year.

 

 

Vaccines turnover

 


Q4 2019








£m


Growth

£%


Growth

CER%







Meningitis

203

 

 

14 

Influenza

138

 

(28)

 

(26)

Shingles

532

 

>100 

 

>100 

Established Vaccines

869

 

(1)

 

2 







 

1,742

 

18 

 

21 

 

 

 

 

 

 

US

909

 

36 

 

40 

Europe

350

 

(7)

 

(4)

International

483

 

11 

 

14 







 

1,742

 

18 

 

21 







 

Vaccines turnover grew 18% AER, 21% CER to £1,742 million, primarily driven by growth in sales of Shingrix.  Meningitis vaccines also contributed to growth, mainly due to higher demand for Menveo in International Influenza vaccines sales declined 28% AER, 26% CER to £138 million, primarily due to the impact of the favourable phasing in Q3 2019 in the US, despite further strong sales execution.  Established Vaccines were down 1% AER but grew 2% CER to £869 million, reflecting higher sales of Synflorix, Hepatitis and Rotarix, partly offset by expected returns on Cervarix due to competitive pressure in China.

 

Meningitis

Meningitis sales grew 8% AER, 14% CER to £203 million.  Bexsero sales declined 2% AER but grew 5% CER to £112 million, driven by strong demand across International and Europe and share gains in the US, partly offset by lower channel inventory and an increased returns provision in the US.  Menveo grew 50% AER, 57% CER, primarily reflecting higher demand and favourable phasing in International, partly offset by lower US sales.

 

Influenza

Fluarix/FluLaval sales declined 28% AER, 26% CER to £138 million, primarily due to the impact of the favourable phasing in Q3 2019 in the US, despite further strong sales execution.

 

Shingles

Shingrix recorded sales of £532 million in the quarter, driven by continued strong uptake and the benefit of prior-period rebate adjustments in the US.  Germany and Canada also contributed to growth.

 

Established Vaccines

Sales of DTPa-containing vaccines (Infanrix, Pediarix and Boostrix) declined 6% AER, 3% CER.  Infanrix, Pediarix sales were down 5% AER, 2% CER to £156 million, reflecting competitive pressures and unfavourable phasing in Europe together with lower demand in the US, partly offset by stronger demand in International.  Boostrix sales declined 6% AER, 4% CER to £130 million, mainly due to the reversal of favourable phasing in International in Q3 2019, partly offset by higher demand and share gains in the US.

 

Hepatitis vaccines grew 3% AER, 6% CER to £195 million, primarily due to the continued benefit from a competitor supply shortage in the US and favourable supply phasing in International, partly offset by lower demand in Europe.

 

Rotarix sales were up 5% AER, 8% CER to £141 million, reflecting stronger demand in the US.

 

Synflorix sales grew 17% AER, 20% CER to £124 million due to higher demand in International, partly offset by lower demand in Europe.

 

MMRV vaccines sales were up 10% AER, 11% CER to £70 million, mainly driven by higher demand in International, partly offset by supply constraints in Europe.

 

 

Consumer Healthcare turnover

 

 



Q4 2019









 



£m

 

Growth

£%

 

Growth

CER%









Wellness

 

 

1,294

 

29

 

31

Oral health

 

 

651

 

4

 

7

Nutrition

 

 

463

 

>100

 

>100

Skin health

 

 

163

 

29

 

32









 

 

 

2,571

 

35

 

37









US

 

 

889

 

82

 

81

Europe

 

 

621

 

14

 

17

International

 

 

1,061

 

21

 

25









 

 

 

2,571

 

35

 

37









Pro-forma growth

 

 

 

 

 

 

-









 

Consumer Healthcare sales grew 35% AER, 37% CER to £2,571 million in the quarter.  On a pro-forma basis, sales were flat, with strong growth in Oral health offset by declines in other categories partly due to the alignment of in-market inventory levels of some Pfizer brands.

 

Divestments and the phasing out of low margin contract manufacturing had a negative impact of approximately one percentage point on pro-forma growth.

 

The legacy Pfizer brands have been included in the existing categories and geographic regions used to report Consumer Healthcare sales.  GSK expects to revise this category structure for reporting from Q1 2020 onwards.

 

Wellness

Wellness sales grew 29% AER, 31% CER to £1,294 million in the quarter.  On a pro-forma basis, sales declined in low single digits, with growth in Pain relief offset by a decline in Respiratory and the phasing out of low margin contract manufacturing.  In Pain relief, Panadol continued to perform strongly, particularly in the Middle East and Africa, and benefited from 2018 regulatory and distribution changes.  Advil growth reflected ongoing recovery from now resolved supply issues.  Pain relief growth was partly offset by a decline in Voltaren, partly reflecting retail stock movements.

 

Oral health

Oral health grew 4% AER, 7% CER to £651 million with strong performance across the category, benefiting from a number of new product innovations during the year.  Sensodyne and Gum health saw double-digit, broad-based growth, while Denture care grew in low single digits.

 

Nutrition

Nutrition sales more than doubled at both AER and CER in the quarter to £463 million, largely due to the inclusion of the Pfizer vitamins, minerals and supplements portfolio.  On a pro-forma basis, sales declined in low single digits, due to the alignment of in-market inventory levels of some Pfizer brands.

 

Skin health

Skin health sales grew 29% AER, 32% CER to £163 million, largely due to the addition of Chapstick from the Pfizer portfolio.  On a pro-forma basis, a decline in sales largely reflected divestments of small tail brands in the US and UK.

 

 

Operating performance

 

Cost of sales

Total cost of sales as a percentage of turnover was 36.5%, 1.1 percentage points higher at AER and 1.1 percentage points higher in CER terms compared with Q4 2018.  This reflected the unwind of the fair market value uplift on inventory arising on completion of the Consumer Healthcare Joint Venture with Pfizer and increased amortisation of intangible assets, partly offset by a reduction in the costs of manufacturing restructuring programmes, primarily as a result of write downs in a number of manufacturing sites in Q4 2018

 

Excluding these and other Adjusting items, Adjusted cost of sales as a percentage of turnover was 32.0%, 1.1 percentage points higher at AER, and 1.1 percentage points higher at CER compared with Q4 2018.  On a pro-forma basis, Adjusted cost of sales as a percentage of turnover was 32.0%, 0.7% percentage points higher at CER compared with Q4 2018.  The increase reflected continued adverse pricing pressure in Pharmaceuticals, particularly in Respiratory, and a non-restructuring related write down in a manufacturing site.  This was partly offset by more favourable product mixes in Pharmaceuticals, due to a reduction in sales of some lower margin established products, and Vaccines, primarily due to the growth of Shingrix in the US.

 

Selling, general and administration

Total SG&A costs as a percentage of turnover were 38.7%, 6.7 percentage points higher at AER and 6.0 percentage points higher on a CER basis compared with Q4 2018.  This included increased Major restructuring costs primarily related to integration of the Consumer Healthcare Joint Venture with Pfizer as well as increased significant legal costs primarily reflecting settlement of existing matters, partly offset by reduced acquisition costs for Tesaro compared with Q4 2018.

 

Excluding these and other Adjusting items, Adjusted SG&A costs as a percentage of turnover were 35.0%, 4.2 percentage points higher at AER than in Q4 2018 and 3.5 percentage points higher on a CER basis.  On a pro-forma basis, Adjusted SG&A costs as a percentage of turnover were 35.0%, 2.8 percentage points higher at CER compared with Q4 2018.  The growth in Adjusted SG&A costs of 23% AER, 23% CER, (11% CER pro-forma) reflected increased investment resulting from the acquisition of Tesaro and in promotional product support, particularly for new launches in Respiratory, HIV and Vaccines.  This was partly offset by the continuing benefit of restructuring in Pharmaceuticals and the tight control of ongoing costs, particularly in non-promotional spending, across all three businesses.

 

Research and development

Total R&D expenditure was £1,243 million (14.0% of turnover), up 16% AER, 17% CER.  Adjusted R&D expenditure was £1,164 million (13.1% of turnover), 14% higher at AER, 16% higher at CER than Q4 2018.  On a pro-forma basis, Adjusted R&D expenditure was 13% higher at CER compared with Q4 2018. 

 

Pharmaceuticals R&D expenditure was £899 million, up 13% AER, 15% CER, reflecting a significant increase in Oncology investment including the assets from the Tesaro acquisition (primarily Zejula and dostarlimab) and a number of other mid and late-stage programmes including belantamab mafodotin, NY-ESO, ICOS and bintrafusp alfa, as well as increased spending on the progression of key non-Oncology assets, such as aGM-CSF for rheumatoid arthritis.  This was partly offset by a favourable comparison with Q4 2018 as a result of significant portfolio reprioritisation.  R&D expenditure in Vaccines and Consumer Healthcare was £186 million and £79 million, respectively.

 

Royalty income

Royalty income was £82 million (Q4 2018: £79 million), up 4% AER, 4% CER, primarily reflecting increased royalties on sales of Gardasil.

 

Other operating income/(expense)

Net other operating income of £855 million (Q4 2018: £122 million expense) primarily reflected net accounting credits of £535 million (Q4 2018: £229 million charges) arising from the re-measurement of the contingent consideration liabilities related to the acquisitions of the former Shionogi-ViiV Healthcare joint venture and the former Novartis Vaccines business and the liabilities for the Pfizer put option and Pfizer and Shionogi preferential dividends in ViiV Healthcare.  This included a re-measurement credit of £390 million (Q4 2018: £261 million charge) for the contingent consideration liability due to Shionogi, primarily arising from changes in exchange rate assumptions and forecast assumptions, partly offset by the unwind of the discount.

 

Other income also included the profit on disposal of the rabies and tick-borne encephalitis vaccines (£306 million) and a number of other asset disposals.  This was partly offset by a decrease in value of the shares in Hindustan Unilever Limited to be received on the disposal of Horlicks and other Consumer Healthcare brands of £105 million in the quarter.  The cumulative increase in value since the signing of the proposed transaction was £240 million.

 

Operating profit

Total operating profit was £1,902 million in Q4 2019 compared with £1,554 million in Q4 2018.  Re-measurement credits on the contingent consideration liabilities, increased profit on disposals and reduced restructuring costs were partly offset by a decrease in the value of the shares in Hindustan Unilever Limited to be received on the disposal of Horlicks and other Consumer Healthcare brands and the unwind of the fair market value uplift on inventory arising on completion of the Consumer Healthcare Joint Venture with Pfizer.

 

Excluding these and other Adjusting items, Adjusted operating profit was £1,852 million, 16% lower than Q4 2018 at AER and 11% lower at CER on a turnover increase of 11% CER.  The Adjusted operating margin of 20.8% was 6.0 percentage points lower at AER and 5.2 percentage points lower on a CER basis than in Q4 2018.  On a pro-forma basis, Adjusted operating profit was 17% lower at CER on a turnover increase of 2% CER.  The Adjusted pro-forma operating margin of 20.8% was 4.8 percentage points lower on a CER basis than in Q4 2018.

 

The reduction in Adjusted operating profit primarily reflected increased investment in R&D, including a significant increase in Oncology, partly on the assets from the Tesaro acquisition, investments in promotional product support, particularly for new launches in Vaccines, HIV and Respiratory, as well as continuing price pressure, particularly in Respiratory, including the impact of the launch of a generic version of Advair in the US in February 2019, together with a non-restructuring related write down in a manufacturing site.  This was partly offset by the benefit from sales growth, particularly in Vaccines, a more favourable mix in Vaccines and continued tight control of ongoing costs, particularly in non-promotional spending, across all three businesses.

 

Contingent consideration cash payments which are made to Shionogi and other companies reduce the balance sheet liability and hence are not recorded in the income statement.  Total contingent consideration cash payments in the quarter amounted to £233 million (Q4 2018: £222 million).  This included cash payments made to Shionogi of £220 million (Q4 2018: £209 million).

 

Operating profit by business

Pharmaceuticals operating profit was £1,008 million, down 35% AER, 33% CER on a turnover decrease of 4% CER.  The operating margin of 22.1% was 10.4 percentage points lower at AER than in Q4 2018 and 10.0 percentage points lower on a CER basis.  This primarily reflected a significant increase in R&D investment, particularly in Oncology, and investment in new product support and targeted priority markets, as well as the continued impact of lower prices, particularly in Respiratory, including the impact of the launch of a generic version of Advair in the US in February 2019 and a non-restructuring related write down in a manufacturing site.  This was partly offset by a favourable product mix, primarily due to a reduction in some lower margin established products, tight control of ongoing costs and the benefits of re-prioritisation of the R&D portfolio.

 

Vaccines operating profit was £578 million, 38% higher than Q4 2018 at AER and 42% higher at CER on a turnover increase of 21% CER.  The operating margin of 33.2% was 4.8 percentage points higher than in Q4 2018 at AER and 4.9 percentage points higher on a CER basis.  This was primarily driven by enhanced operating leverage from strong sales growth, particularly Shingrix in the US, and improved product mix, partly offset by higher supply chain costs.

 

Consumer Healthcare operating profit was £440 million, up 25% AER, 33% CER on a turnover increase of 37% CER.  On a pro-forma basis operating profit of £440 million was down 8% CER with turnover flat at CER.  The operating margin of 17.1% was 1.3 percentage points lower at AER and 0.6 percentage points lower on a CER basis.  The pro-forma operating margin of 17.1% was 1.6 percentage points lower on a CER basis than in Q4 2018.  This primarily reflected reduced growth from higher margin power brands in the quarter following earlier seasonal sell-ins, increased promotional investment and unfavourable inventory adjustments, partly offset by continued manufacturing restructuring savings.  Growth was also adversely affected by a different central cost allocation methodology applied by Pfizer in the comparative pro-forma financial information.

 

Net finance costs

Total net finance costs were £195 million compared with £185 million in Q4 2018.  Adjusted net finance costs were £197 million compared with £173 million in Q4 2018.  The increase primarily reflected higher debt levels reflecting the acquisition of Tesaro in January 2019.  Following the introduction of IFRS 16, 'Leases', finance costs included an unwind of the discount on the lease liability of £10 million in the quarter.

 

Share of after tax profits of associates and joint ventures

The share of after tax profits of associates was £4 million (Q4 2018: £5 million).

 

Taxation

The charge of £194 million represented an effective tax rate on Total results of 11.3% (Q4 2018: 5.4%) and reflected the different tax effects of the various Adjusting items.  Tax on Adjusted profit amounted to £207 million and represented an effective Adjusted tax rate of 12.5% (Q4 2018: 17.5%), reflecting the impact of the settlement of a number of open issues with tax authorities.

 

Issues related to taxation are described in Note 14, 'Taxation' in the Annual Report 2018.  The Group continues to believe it has made adequate provision for the liabilities likely to arise from periods which are open and not yet agreed by tax authorities.  The ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of agreements with relevant tax authorities.

 

Non-controlling interests

The allocation of Total earnings to non-controlling interests amounted to £218 million (Q4 2018: £85 million).  The increase was primarily due to an increased allocation of ViiV Healthcare profits of £192 million (Q4 2018: £78 million) including charges for movements in contingent consideration liabilities and the allocation of Pfizer's interest in the profits of the Consumer Healthcare Joint Venture (£23 million), partly offset by lower net profits in some of the Group's other entities with non-controlling interests.

 

The allocation of Adjusted earnings to non-controlling interests amounted to £225 million (Q4 2018: £139 million).  The increase in allocation was primarily due to the allocation of Pfizer's interest in the profits of the Consumer Healthcare Joint Venture (£101 million), partly offset by a reduced allocation of ViiV Healthcare profits of £121 million (Q4 2018: £130 million) and lower net profits in some of the Group's other entities with non-controlling interests.

 

Earnings per share

Total earnings per share was 26.2p, compared with 24.7p in Q4 2018.  The increase in earnings per share primarily reflected re-measurement credits on the contingent consideration liabilities, increased profit on disposals and reduced restructuring costs, partly offset by a decrease in the value of the shares in Hindustan Unilever Limited to be received on the disposal of Horlicks and other Consumer Healthcare brands and the unwind of the fair market value uplift on inventory arising on completion of the Consumer Healthcare Joint Venture with Pfizer.

 

Adjusted EPS of 24.8p compared with 31.2p in Q4 2018, down 21% AER, 16% CER, on an 11% CER decrease in Adjusted operating profit.  This reflected an increased non-controlling interest allocation of Consumer Healthcare profits following the creation of the new Consumer Healthcare Joint Venture in Q3 2019 and increased net finance costs, partly offset by a reduced effective tax rate.

 

Currency impact on Q4 2019 results

The Q4 2019 results are based on average exchange rates, principally £1/$1.30, £1/€1.17 and £1/Yen 141.  Comparative exchange rates are given on page 56.  The period-end exchange rates were £1/$1.32, £1/€1.18 and £1/Yen 143.

 

In the quarter, turnover increased 9% AER, 11% CER.  Total EPS was 26.2p compared with 24.7p in Q4 2018.  Adjusted EPS was 24.8p compared with 31.2p in Q4 2018, down 21% AER, 16% CER.  The negative currency impact primarily reflected the strength of Sterling, particularly against the US$, Euro and emerging market currencies, relative to Q4 2018.  Exchange gains or losses on the settlement of intercompany transactions represented one percentage point of the negative currency impact of five percentage points on Adjusted EPS.

 

 

Adjusting items

The reconciliations between Total results and Adjusted results for Q4 2019 and Q4 2018 are set out below.

 

Three months ended 31 December 2019

 


Total

results

£m

Intangible

amort-

isation

£m

Intangible

impair-

ment

£m

Major

restruct-

uring

£m

Transaction-

related

£m

Divestments,

significant

legal and

other items

£m

Adjusted

results

£m


------------

------------

------------

------------

------------

------------

------------

Turnover

8,899 






8,899 

Cost of sales

(3,248)

163 

3 

11 

223 


(2,848)


------------

------------

------------

------------

------------

------------

------------

Gross profit

5,651 

163 

3 

11 

223 


6,051 









Selling, general and administration

(3,443)


(1)

163 

4 

160 

(3,117)

Research and development

(1,243)

16 

19 

43 


1 

(1,164)

Royalty income

82 






82 

Other operating income/(expense)

855 




(557)

(298)

- 


------------

------------

------------

------------

------------

------------

------------

Operating profit

1,902 

179 

21 

217 

(330)

(137)

1,852 









Net finance costs

(195)



1 


(3)

(197)

Share of after tax profits of

  associates and joint ventures

4 






4 


------------

------------

------------

------------

------------

------------

------------

Profit before taxation

1,711 

179 

21 

218 

(330)

(140)

1,659 









Taxation

(194)

(41)

(6)

(58)

15 

77 

(207)

Tax rate %

11.3%






12.5%


------------

------------

------------

------------

------------

------------

------------

Profit after taxation

1,517 

138 

15 

160 

(315)

(63)

1,452 


------------

------------

------------

------------

------------

------------

------------

Profit attributable to

  non-controlling interests

218 




7 


225 









Profit attributable to

  shareholders

1,299 

138 

15 

160 

(322)

(63)

1,227 


------------

------------

------------

------------

------------

------------

------------









Earnings per share

26.2p

2.8p

0.3p

3.2p

(6.5)p

(1.2)p

24.8p


------------

------------

------------

------------

------------

------------

------------

















Weighted average number of

  shares (millions)

4,953 






4,953 


------------






------------

 

 

Three months ended 31 December 2018

 


Total

results

£m

Intangible

amort-

isation

£m

Intangible

impair-

ment

£m

Major

restruct-

uring

£m

Transaction-

related

£m

Divestments,

significant

legal and

other items

£m

Adjusted

results

£m


------------

------------

------------

------------

------------

------------

------------

Turnover

8,197 






8,197 

Cost of sales

(2,904)

136 


232 

4 


(2,532)


------------

------------

------------

------------

------------

------------

------------

Gross profit

5,293 

136 


232 

4 


5,665 









Selling, general and administration

(2,620)



48 

37 

6 

(2,529)

Research and development

(1,076)

14 

12 

22 


9 

(1,019)

Royalty income

79 






79 

Other operating (expense)/income

(122)



1 

230 

(109)

- 


------------

------------

------------

------------

------------

------------

------------

Operating profit

1,554 

150 

12 

303 

271 

(94)

2,196 









Net finance costs

(185)



2 

(3)

13 

(173)

Share of after tax profits of

  associates and joint ventures

5 






5 


------------

------------

------------

------------

------------

------------

------------

Profit before taxation

1,374 

150 

12 

305 

268 

(81)

2,028 









Taxation

(74)

(24)

(4)

(48)

(38)

(167)

(355)

Tax rate %

5.4%






17.5%


------------

------------

------------

------------

------------

------------

------------

Profit after taxation

1,300 

126 

8 

257 

230 

(248)

1,673 


------------

------------

------------

------------

------------

------------

------------

Profit attributable to

  non-controlling interests

85 




54 


139 









Profit attributable to

  shareholders

1,215 

126 

8 

257 

176 

(248)

1,534 


------------

------------

------------

------------

------------

------------

------------









Earnings per share

24.7p

2.6p

0.2p

5.2p

3.6p

(5.1)p

31.2p


------------

------------

------------

------------

------------

------------

------------

















Weighted average number of

  shares (millions)

4,920 






4,920 


------------






------------

 

Major restructuring and integration

Within the Pharmaceuticals sector, the highly regulated manufacturing operations and supply chains and long lifecycle of the business mean that restructuring programmes, particularly those that involve the rationalisation or closure of manufacturing or R&D sites are likely to take several years to complete.

 

Total Major restructuring charges incurred in the quarter were £217 million (Q4 2018: £303 million), analysed as follows:

 


Q4 2019


Q4 2018














Cash

£m


Non-cash

£m


Total

£m


Cash

£m


Non-cash

£m


Total

£m













2018 major restructuring

  programme (incl. Tesaro)

48

 

23

 

71

 

151

 

90

 

241

Consumer Healthcare Joint

  Venture integration

  Programme

113

 

4

 

117

 

-

 

-

 

-

Combined restructuring and

  integration programme

18

 

11

 

29

 

52

 

10

 

62













 

179

 

38

 

217

 

203

 

100

 

303













 

Cash charges arose from integration costs under the Consumer Healthcare Joint Venture integration programme as well as restructuring of the manufacturing organisation, R&D and some administrative functions, and the integration of Tesaro under the 2018 major restructuring programme.  Non-cash charges arising under the 2018 major restructuring programme and Combined restructuring and integration programme primarily related to the write-down of assets as part of announced plans to reduce the manufacturing network.

 

Total cash payments made in the quarter were £255 million, £69 million for the existing Combined restructuring and integration programme (Q4 2018: £175 million) and £79 million under the 2018 major restructuring programme (Q4 2018: £9 million), including the settlement of certain charges accrued in previous quarters, and a further £107 million relating to the Consumer Healthcare Joint Venture integration programme.

 

The analysis of Major restructuring charges by business was as follows:

 

 

Q4 2019

£m

 

Q4 2018

£m

 




Pharmaceuticals

36

 

269 

Vaccines

10

 

28 

Consumer Healthcare

134

 

(28)





 

180

 

269 

Corporate & central functions

37

 

34 

 




Total Major restructuring costs

217

 

303 





 

The analysis of Major restructuring charges by Income statement line was as follows:

 

 

Q4 2019

£m

 

Q4 2018

£m

 




Cost of sales

11

 

232 

Selling, general and administration

163

 

48 

Research and development

43

 

22 

Other operating expense

-

 

 




Total Major restructuring costs

217

 

303 





 

The Major restructuring programmes delivered incremental cost savings in the quarter of £0.2 billion.

 

Transaction-related adjustments

Transaction-related adjustments resulted in a net credit of £330 million (Q4 2018: £271 million charge).  This primarily reflected £535 million of net accounting credits for the re-measurement of the contingent consideration liabilities related to the acquisitions of the former Shionogi-ViiV Healthcare joint venture and the former Novartis Vaccines business and the liabilities for the Pfizer put option and Pfizer and Shionogi preferential dividends in ViiV Healthcare.

 

(Credit)/charge

Q4 2019

£m

 

Q4 2018

£m





Contingent consideration on former Shionogi-ViiV Healthcare joint venture

  (including Shionogi preferential dividends)

(390)

 

261 

ViiV Healthcare put options and Pfizer preferential dividends

(153)

 

(40)

Contingent consideration on former Novartis Vaccines business

8 

 

Release of fair value uplift on acquired Pfizer inventory

218 

 

Other adjustments

(13)

 

42 





Total transaction-related charges

(330)

 

271 





 

The £390 million credit relating to the contingent consideration for the former Shionogi-ViiV Healthcare joint venture represented a decrease in the valuation of the contingent consideration due to Shionogi, primarily as a result of updated exchange rate assumptions as well as sales forecasts, partly offset by a £112 million unwind of the discount.

 

An explanation of the accounting for the non-controlling interests in ViiV Healthcare is set out on page 10.

 

Divestments, significant legal charges and other items

Divestments and other items included a profit on the disposal of the rabies and tick-borne encephalitis vaccines (£306 million) and a number of other assets, partly offset by a loss in the quarter of £105 million arising from the decrease in value of the shares in Hindustan Unilever Limited to be received on the disposal of Horlicks and other Consumer Healthcare brands and a charge of £164 million (Q4 2018: £4 million) for significant legal matters reflecting the settlement of existing matters as well as provisions for ongoing litigation.  Significant legal cash payments were £281 million (Q4 2018: £15 million).

 

 

Cash generation

 

Cash flow

 


2019


2018


Q4 2019







Net cash inflow from operating activities (£m)

8,020 

 

8,421 

 

3,453 

Free cash flow* (£m)

5,073 

 

5,692 

 

2,599 

Free cash flow growth (%)

(11)%

 

63%

 

(22)%

Free cash flow conversion* (%)

>100%

 

>100%

 

>100%

Net debt** (£m)

25,215 

 

21,621 

 

25,215 

 

*

Free cash flow and free cash flow conversion are defined on page 60.

**

Net debt is analysed on page 59.

 

2019

The net cash inflow from operating activities for the year was £8,020 million (2018: £8,421 million).  Free cash flow was £5,073 million (2018: £5,692 million).  The reduction primarily reflected the adverse timing of payments for returns and rebates, as well as the initial step-down impact from US Advair generic competition, increased capital expenditure including the acquisition of intangible assets, higher restructuring payments and higher significant legal costs.  This was partly offset by improved operating profits including currency benefits, a reduction in inventory and lower increase in trade receivables, lower contingent consideration payments compared with 2018, which included a milestone payment to Novartis, lower dividend payments to non-controlling interests and the reclassification of lease payments from operating to financing activities following the transition to IFRS 16.  

 

Total cash payments to Shionogi in relation to the ViiV Healthcare contingent consideration liability in the year were £865 million (2018: £793 million), of which £767 million was recognised in cash flows from operating activities and £98 million was recognised in contingent consideration paid within investing cash flows.  These payments are deductible for tax purposes.

 

Q4 2019

Net cash inflow from operating activities for the quarter was £3,453 million (Q4 2018: £4,119 million).  Free cash flow was £2,599 million (Q4 2018: £3,317 million).  The reduction primarily reflected the adverse timing of payments for returns and rebates and the step-down impact from US Advair generic competition, higher significant legal payments and lower operating profits including the effects of currency.  This was partly offset by a greater seasonal reduction in inventory and trade receivables and the reclassification of lease payments from operating to financing activities following the transition to IFRS 16.

 

Total cash payments to Shionogi in relation to the ViiV Healthcare contingent consideration liability in the quarter were £220 million (Q4 2018: £209 million), of which £195 million was recognised in cash flows from operating activities and £25 million was recognised in contingent consideration paid within investing cash flows.  These payments are deductible for tax purposes.

 

Net debt

At 31 December 2019, net debt was £25.2 billion, compared with £21.6 billion at 31 December 2018, comprising gross debt of £30.5 billion and cash and liquid investments of £5.3 billion, including £0.5 billion reported within Assets held for sale.  Net debt increased due to the £3.9 billion acquisition of Tesaro Inc as well as £0.2 billion of Tesaro net debt, together with the £1.3 billion impact from the implementation of IFRS 16, the dividend paid to shareholders of £4.0 billion and other net investing activities of £0.1 billion, partly offset by £0.7 billion net favourable exchange impacts from the translation of non-Sterling denominated debt and exchange on other financing items and £5.1 billion of free cash flow.

 

At 31 December 2019, GSK had short-term borrowings (including overdrafts and lease liabilities) repayable within 12 months of £6.9 billion with loans of £3.2 billion repayable in the subsequent year.

 

 

Returns to shareholders

 

Quarterly dividends

The Board has declared a fourth interim dividend for 2019 of 23 pence per share (Q4 2018: 23 pence per share).

 

GSK recognises the importance of dividends to shareholders and aims to distribute regular dividend payments that will be determined primarily with reference to the free cash flow generated by the business after funding the investment necessary to support the Group's future growth.

 

The Board intends to maintain the dividend for 2020 at the current level of 80p per share, subject to any material change in the external environment or performance expectations.  Over time, as free cash flow strengthens, it intends to build free cash flow cover of the annual dividend to a target range of 1.25-1.50x, before returning the dividend to growth.

 

Payment of dividends

The equivalent interim dividend receivable by ADR holders will be calculated based on the exchange rate on 7 April 2020.  An annual fee of $0.03 per ADS (or $0.0075 per ADS per quarter) (2018: $0.02 per ADS; $0.005 per ADS per quarter) is charged by the Depositary.

 

The ex-dividend date will be 20 February 2020, with a record date of 21 February 2020 and a payment date of 9 April 2020.

 


Paid/

payable


Pence per

share


£m







2019

 

 

 

 

 

First interim

11 July 2019

 

19

 

940

Second interim

10 October 2019

 

19

 

941

Third interim

9 January 2020

 

19

 

941

Fourth interim

9 April 2020

 

23

 

1,139







 

 

 

80

 

3,961







 

2018

 

 

 

 

 

First interim

12 July 2018

 

19

 

934

Second interim

11 October 2018

 

19

 

934

Third interim

10 January 2019

 

19

 

935

Fourth interim

11 April 2019

 

23

 

1,137







 

 

 

80

 

3,940







 

 

Weighted average number of shares

 

 

 

 

 

 

 

2019

millions


2018

millions







Weighted average number of shares - basic

 

 

4,947

 

4,914

Dilutive effect of share options and share awards

 

 

69

 

57







Weighted average number of shares - diluted

 

 

5,016

 

4,971







 

Weighted average number of shares

 

 

 

 

 

 

 

Q4 2019

millions


Q4 2018

millions







Weighted average number of shares - basic

 

 

4,953

 

4,920

Dilutive effect of share options and share awards

 

 

69

 

58







Weighted average number of shares - diluted

 

 

5,022

 

4,978







 

At 31 December 2019, 4,953 million shares (2018: 4,923 million) were in free issue (excluding Treasury shares and shares held by the ESOP Trusts).  GSK made no share repurchases during the year.  The company issued 4.0 million shares under employee share schemes in the year for proceeds of £51 million (2018: £74 million).

 

At 31 December 2019, the ESOP Trust held 36.0 million GSK shares against the future exercise of share options and share awards.  The carrying value of £135 million has been deducted from other reserves.  The market value of these shares was £647 million.

 

At 31 December 2019, the company held 393.5 million Treasury shares at a cost of £5,505 million, which has been deducted from retained earnings.

 

 

Financial information

 

Income statements

 


2019

£m


2018

£m


Q4 2019

£m


Q4 2018

£m









TURNOVER

33,754 

 

30,821 

 

8,899 

 

8,197 









Cost of sales

(11,863)

 

(10,241)

 

(3,248)

 

(2,904)









Gross profit

21,891 

 

20,580 

 

5,651 

 

5,293 









Selling, general and administration

(11,402)

 

(9,915)

 

(3,443)

 

(2,620)

Research and development

(4,568)

 

(3,893)

 

(1,243)

 

(1,076)

Royalty income

351 

 

299 

 

82 

 

79 

Other operating income/(expense)

689 

 

(1,588)

 

855 

 

(122)









OPERATING PROFIT

6,961 

 

5,483 

 

1,902 

 

1,554 









Finance income

98 

 

81 

 

11 

 

24 

Finance expense

(912)

 

(798)

 

(206)

 

(209)

Profit on disposal of associates

- 

 

 

- 

 

Share of after tax profits of

  associates and joint ventures

74 

 

31 

 

4 

 









PROFIT BEFORE TAXATION

6,221 

 

4,800 

 

1,711 

 

1,374









Taxation

(953)

 

(754)

 

(194)

 

(74)

Tax rate %

15.3%

 

15.7%

 

11.3%

 

5.4%









PROFIT AFTER TAXATION

5,268 

 

4,046 

 

1,517 

 

1,300 









Profit attributable to non-controlling

  interests

623 

 

423 

 

218 

 

85 

Profit attributable to shareholders

4,645 

 

3,623 

 

1,299 

 

1,215 









 

5,268 

 

4,046 

 

1,517 

 

1,300 









EARNINGS PER SHARE

93.9p

 

73.7p

 

26.2p

 

24.7p

 

 

 

 

 

 

 

 

Diluted earnings per share

92.6p

 

72.9p

 

25.9p

 

24.4p









 

 

Statement of comprehensive income

 

 

2019

£m

 

2018

£m





Profit for the year

5,268 

 

4,046 

 

 

 

 

Items that may be reclassified subsequently to income statement:

 

 

 

Exchange movements on overseas net assets and net investment hedges

(832)

 

(480)

Reclassification of exchange movements on liquidation or disposal of

  overseas subsidiaries

(75)

 

Fair value movements on cash flow hedges

(20)

 

140 

Reclassification of cash flow hedges to income statement

3 

 

(175)

Deferred tax on fair value movements on cash flow hedges

16 

 

(22)

Deferred tax reversed on reclassification of cash flow hedges

- 

 

20 





 

(908)

 

(517)





Items that will not be reclassified to income statement:

 

 

 

Exchange movements on overseas net assets of non-controlling interests

(75)

 

(1)

Fair value movements on equity investments

372 

 

180 

Deferred tax on fair value movements on equity investments

(95)

 

10 

Re-measurement (losses)/gains on defined benefit plans

(1,050)

 

728 

Tax on re-measurement (losses)/gains on defined benefit plans

189 

 

(146)





 

(659)

 

771 





Other comprehensive (expense)/income for the year

(1,567)

 

254 





Total comprehensive income for the year

3,701 

 

4,300 





 

 

 

 

Total comprehensive income for the year attributable to:

 

 

 

  Shareholders

3,153 

 

3,878 

  Non-controlling interests

548 

 

422 





 

3,701 

 

4,300 





 

 

Statement of comprehensive income

 

 

Q4 2019

£m

 

Q4 2018

£m





Profit for the period

1,517 

 

1,300 

 

 

 

 

Items that may be reclassified subsequently to income statement:

 

 

 

Exchange movements on overseas net assets and net investment hedges

(637)

 

(112)

Reclassification of exchange movements on liquidation or disposal of

  overseas subsidiaries

(75)

 

Fair value movements on cash flow hedges

86 

 

(42)

Reclassification of cash flow hedges to income statement

- 

 

(11)

Deferred tax on fair value movements on cash flow hedges

16 

 





 

(610)

 

(163)





Items that will not be reclassified to income statement:

 

 

 

Exchange movements on overseas net assets of non-controlling interests

(103)

 

18 

Fair value movements on equity investments

276 

 

(88)

Deferred tax on fair value movements on equity investments

(68)

 

23 

Re-measurement gains/(losses) on defined benefit plans

142 

 

(375)

Tax on re-measurement gains/(losses) on defined benefit plans

(26)

 

59 





 

221 

 

(363)





Other comprehensive expense for the period

(389)

 

(526)





Total comprehensive income for the period

1,128 

 

774 





 

 

 

 

Total comprehensive income for the period attributable to:

 

 

 

  Shareholders

1,013 

 

671 

  Non-controlling interests

115 

 

103 





 

1,128 

 

774 





 

 

Pharmaceuticals turnover - year ended 31 December 2019

 


Total

US

Europe

International


---------------------------------------

---------------------------------------

---------------------------------------

---------------------------------------








------------------------


------------------------


------------------------


------------------------


£m

£%

CER%

£m

£%

CER%

£m

£%

CER%

£m

£%

CER%


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------














Respiratory

3,081

18 

15 

1,742 

10 

6 

783

29 

29 

556

33 

31 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Ellipta products

2,313

13 

10 

1,289 

4 

- 

577

26 

27 

447

29 

27 

  Anoro Ellipta

514

8 

5 

324 

2 

(2)

120

19 

20 

70

23 

21 

  Arnuity Ellipta

48

9 

5 

41 

5 

3 

-

- 

- 

7

40 

20 

  Incruse Ellipta

262

(8)

(10)

161 

(13)

(17)

73

(1)

(1)

28

17 

17 

  Relvar/Breo Ellipta

971

(11)

(13)

381 

(34)

(37)

282

11 

12 

308

21 

19 

  Trelegy Ellipta

518

>100 

>100 

382 

>100 

>100 

102

>100 

>100 

34

>100 

>100 














Nucala

768

36 

33 

453 

33 

28 

206

36 

37 

109

56 

50 














HIV

4,854

3 

1 

3,004 

3 

(1)

1,156

(3)

(2)

694

13 

13 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Dolutegravir products

4,633

5 

2 

2,938 

4 

- 

1,086

- 

- 

609

22 

22 

  Tivicay

1,662

1 

(1)

977 

(6)

(9)

395

5 

6 

290

28 

28 

  Triumeq

2,549

(4)

(6)

1,611 

(4)

(7)

626

(11)

(11)

312

15 

15 

  Juluca

366

>100 

>100 

303 

>100 

>100 

56

>100 

>100 

7

>100 

>100 

  Dovato

56

- 

- 

47 

- 

- 

9

- 

- 

-

- 

- 














Epzicom/Kivexa

75

(36)

(35)

3 

(57)

(57)

23

(48)

(48)

49

(26)

(24)

Selzentry

97

(16)

(17)

53 

(9)

(12)

29

(17)

(14)

15

(32)

(32)

Other

49

(30)

(31)

10 

(44)

(44)

18

(25)

(29)

21

(25)

(25)














Immuno-

inflammation

613

30 

25 

535 

27 

23 

46

28 

28 

32

>100 

94 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Benlysta

613

30 

25 

535 

27 

23 

46

24 

24 

32

>100 

94 














Oncology

230

- 

- 

134 

- 

- 

96

- 

- 

-

- 

- 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Zejula

229

- 

- 

134 

- 

- 

95

- 

- 

-

- 

- 














Established

Pharmaceuticals

8,776

(7)

(8)

1,987 

(22)

(24)

2,044

(8)

(8)

4,745

1 

1 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Established

Respiratory

3,900

(10)

(11)

1,415 

(21)

(23)

807

(13)

(12)

1,678

4 

3 

  Seretide/Advair

1,730

(29)

(29)

502 

(54)

(56)

502

(16)

(16)

726

- 

(1)

  Flixotide/Flovent

629

6 

4 

368 

11 

6 

88

(5)

(4)

173

2 

2 

  Ventolin

938

27 

25 

547 

55 

49 

120

(8)

(7)

271

6 

7 

  Avamys/Veramyst

324

8 

6 

(2)

>(100)

>(100)

69

(7)

(5)

257

14 

11 

  Other

279

6 

2 

- 

- 

- 

28

- 

(4)

251

7 

3 














Dermatology

445

2 

3 

3 

- 

- 

159

(1)

(1)

283

4 

6 

Augmentin

602

6 

6 

- 

- 

- 

172

(5)

(4)

430

11 

11 

Avodart

574

- 

(1)

4 

(67)

(67)

208

(13)

(12)

362

13 

11 

Imigran/Imitrex

138

(2)

(3)

59 

2 

- 

52

(9)

(7)

27

4 

- 

Lamictal

566

(8)

(10)

284 

(8)

(12)

112

(1)

- 

170

(12)

(13)

Seroxat/Paxil

160

(6)

(6)

- 

- 

- 

37

(5)

(5)

123

(6)

(7)

Valtrex

107

(13)

(15)

14 

(33)

(38)

31

3 

3 

62

(14)

(15)

Other

2,284

(9)

(9)

208 

(40)

(43)

466

(5)

(4)

1,610

(4)

(4)


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Pharmaceuticals

17,554

2 

- 

7,402 

(1)

(4)

4,125

1 

2 

6,027

5 

4 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------














 

 

Pharmaceuticals turnover - three months ended 31 December 2019

 


Total

US

Europe

International


---------------------------------------

---------------------------------------

---------------------------------------

---------------------------------------








------------------------


------------------------


------------------------


------------------------


£m

£%

CER%

£m

£%

CER%

£m

£%

CER%

£m

£%

CER%


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------














Respiratory

892

8 

9 

521 

- 

1 

214

20 

22 

157

23 

22 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Ellipta products

674

3 

4 

389 

(6)

(5)

158

17 

19 

127

20 

19 

  Anoro Ellipta

141

(2)

(1)

91 

(7)

(6)

33

14 

17 

17

- 

- 

  Arnuity Ellipta

15

15 

15 

13 

18 

18 

-

- 

- 

2

- 

- 

  Incruse Ellipta

77

(11)

(10)

52 

(13)

(12)

18

(10)

(10)

7

- 

- 

  Relvar/Breo Ellipta

269

(19)

(19)

107 

(42)

(41)

74

4 

6 

88

16 

14 

  Trelegy Ellipta

172

>100 

>100 

126 

>100 

>100 

33

>100 

>100 

13

>100 

>100 














Nucala

218

26 

28 

132 

23 

24 

56

27 

32 

30

36 

36 














HIV

1,257

(1)

- 

782 

(1)

1 

296

(7)

(4)

179

3 

5 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Dolutegravir products

1,208

- 

2 

768 

- 

2 

278

(4)

(1)

162

9 

11 

  Tivicay

426

(6)

(4)

244 

(13)

(11)

100

(4)

(1)

82

22 

22 

  Triumeq

638

(8)

(5)

408 

(5)

(3)

153

(16)

(13)

77

(4)

- 

  Juluca

111

79 

79 

89 

59 

59 

19

>100 

>100 

3

>100 

100 

  Dovato

33

- 

- 

27 

- 

- 

6

- 

- 

-

- 

- 














Epzicom/Kivexa

15

(50)

(47)

- 

- 

- 

5

(55)

(55)

10

(33)

(27)

Selzentry

23

(26)

(23)

13 

(19)

(19)

7

(22)

(11)

3

(50)

(50)

Other

11

10 

- 

1 

>100 

>100 

6

- 

(17)

4

- 

- 














Immuno-

inflammation

170

25 

26 

148 

22 

25 

12

20 

20 

10

>100 

60 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Benlysta

170

23 

24 

148 

22 

25 

12

20 

20 

10

43 

14 














Oncology

66

- 

- 

37 

- 

- 

29

- 

- 

-

- 

- 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Zejula

66

- 

- 

37 

- 

- 

29

- 

- 

-

- 

- 














Established

Pharmaceuticals

2,173

(15)

(14)

470 

(32)

(31)

497

(18)

(15)

1,206

(5)

(4)


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Established

Respiratory

965

(17)

(16)

341 

(32)

(31)

196

(17)

(15)

428

1 

1 

  Seretide/Advair

414

(36)

(35)

104 

(65)

(64)

119

(21)

(18)

191

(4)

(4)

  Flixotide/Flovent

186

12 

13 

115 

22 

22 

22

(15)

(12)

49

7 

9 

  Ventolin

226

5 

8 

124 

13 

16 

31

(14)

(11)

71

3 

4 

  Avamys/Veramyst

72

(1)

- 

(2)

>(100)

>(100)

15

(12)

(6)

59

5 

5 

  Other Respiratory

67

6 

3 

- 

- 

- 

9

29 

- 

58

4 

4 














Dermatology

112

(3)

1 

- 

- 

- 

40

(7)

(5)

72

1 

6 

Augmentin

158

8 

11 

- 

- 

- 

47

(4)

(2)

111

14 

18 

Avodart

140

(6)

(5)

- 

- 

- 

48

(20)

(15)

92

7 

6 

Imigran/Imitrex

35

(12)

(10)

15 

(21)

(16)

13

(7)

- 

7

- 

(14)

Lamictal

145

(9)

(8)

73 

(12)

(11)

28

(7)

- 

44

(4)

(9)

Seroxat/Paxil

38

(17)

(15)

- 

- 

- 

9

(10)

(10)

29

(19)

(17)

Valtrex

27

(18)

(18)

4 

(43)

(43)

8

14 

14 

15

(21)

(21)

Other

553

(23)

(20)

37 

(51)

(54)

108

(30)

(29)

408

(16)

(12)


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Pharmaceuticals

4,558

(5)

(4)

1,958 

(8)

(6)

1,048

(6)

(3)

1,552

(2)

- 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------














 

 

Vaccines turnover - year ended 31 December 2019

 


Total

US

Europe

International


---------------------------------------

---------------------------------------

---------------------------------------

---------------------------------------



Growth


Growth


Growth


Growth



------------------------


------------------------


------------------------


------------------------


£m

£%

CER%

£m

£%

CER%

£m

£%

CER%

£m

£%

CER%


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------














Meningitis

1,018

16 

15 

430

15 

10 

343

2 

3 

245

43 

50 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Bexsero

679

16 

16 

260

30 

25 

319

3 

4 

100

37 

48 

Menveo

267

15 

13 

170

(2)

(6)

18

6 

6 

79

93 

100 

Other

72

11 

11 

-

- 

- 

6

(25)

(25)

66

16 

16 














Influenza

541

3 

1 

412

7 

3 

56

(15)

(15)

73

1 

4 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Fluarix, FluLaval

541

3 

1 

412

7 

3 

56

(15)

(15)

73

1 

4 














Shingles

1,810

>100 

>100 

1,669

>100 

>100 

54

>100 

>100 

87

78 

76 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Shingrix

1,810

>100 

>100 

1,669

>100 

>100 

54

>100 

>100 

87

78 

76 














Established

Vaccines

3,788

2 

1 

1,394

15 

11 

1,035

(11)

(10)

1,359

1 

2 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Infanrix, Pediarix

733

8 

6 

360

22 

17 

213

(20)

(19)

160

36 

35 

Boostrix

584

13 

11 

299

13 

9 

156

(4)

(3)

129

43 

44 














Hepatitis

874

8 

6 

529

16 

11 

231

(6)

(5)

114

9 

10 














Rotarix

558

7 

6 

140

11 

6 

112

2 

3 

306

7 

8 














Synflorix

468

10 

11 

-

- 

- 

54

(7)

(5)

414

13 

13 














Priorix, Priorix Tetra,

  Varilrix

232

(24)

(23)

-

- 

- 

100

(37)

(37)

132

(9)

(9)

Cervarix

50

(64)

(64)

-

- 

- 

21

5 

5 

29

(75)

(76)

Other

289

(8)

(7)

66

3 

2 

148

8 

10 

75

(33)

(33)


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Vaccines

7,157

21 

19 

3,905

45 

39 

1,488

(5)

(4)

1,764

8 

9 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------














 

 

Vaccines turnover - three months ended 31 December 2019

 


Total

US

Europe

International


---------------------------------------

---------------------------------------

---------------------------------------

---------------------------------------



Growth


Growth


Growth


Growth



------------------------


------------------------


------------------------


------------------------


£m

£%

CER%

£m

£%

CER%

£m

£%

CER%

£m

£%

CER%


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------














Meningitis

203 

8 

14 

25

(50)

(36)

83

6 

9 

95 

58 

62 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Bexsero

112 

(2)

5 

12

(48)

(26)

76

6 

8 

24 

26 

32 

Menveo

66 

50 

57 

13

(52)

(44)

6

50 

50 

47 

>100 

>100 

Other

25 

(17)

(17)

-

- 

- 

1

(50)

(50)

24 

(14)

(14)














Influenza

138 

(28)

(26)

92

(32)

(30)

22

(29)

(29)

24 

(11)

(4)


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Fluarix, FluLaval

138 

(28)

(26)

92

(32)

(30)

22

(29)

(29)

24 

(11)

(4)














Shingles

532 

>100 

>100 

494

>100 

>100 

19

>100 

>100 

19 

27 

40 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Shingrix

532 

>100 

>100 

494

>100 

>100 

19

>100 

>100 

19 

27 

40 














Established

Vaccines

869 

(1)

2 

298

8 

12 

226

(15)

(12)

345 

3 

5 


---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

---------

Infanrix, Pediarix

156 

(5)

(2)

68

(9)

(7)

44

(27)

(23)

44 

47 

50 

Boostrix

130 

(6)

(4)

66

3 

6 

34

(8)

(5)

30 

(21)

(18)














Hepatitis

195 

3 

6 

111

8 

11 

53

(12)

(8)

31 

15 

22 














Rotarix

141 

5 

8 

34

36 

36 

28

- 

- 

79 

(2)

2 














Synflorix

124 

17 

20 

-

- 

- 

10

(52)

(48)

114 

34 

36 














Priorix, Priorix Tetra,

  Varilrix

70 

10 

11 

-

- 

- 

26

(20)

(20)

44 

40 

43 

Cervarix

(13)

>(100)